

**Organocatalytic Enantioselective Tandem Michael-Cyclization of Isatin Derived
 β, γ -Unsaturated α -Ketoesters with 3-Hydroxy-4H-Chromen-4-One or 2-
Hydroxy-1,4-Naphthoquinone Derivatives**

Shao-Jie Yin, Shao-Yun Zhang, Jun-Qi Zhang, Bing-Bing Sun, Wei-Tai Fan, Bing
Wu and Xing-Wang Wang*

*Key Laboratory of Organic Synthesis of Jiangsu Province, College of Chemistry,
Chemical Engineering and Materials Science, Soochow University, Suzhou 215123,
People's Republic of China*

Fax: +(86)512-6588-0378

E-mail: wangxw@suda.edu.cn



1. General information.....	2
2. Optimization of reaction.....	3
3. Experimental data.....	5
4. ^1H NMR and ^{13}C NMR.....	38
5. HPLC spectra.....	83
6. X-ray data of rac-4u.....	121

1. General information :

Unless otherwise stated, all reagents were purchased from commercial suppliers and used without further purification. All reactions were carried out in air and using undistilled solvents, without any precautions to exclude moisture unless otherwise noted. Organic solutions were concentrated under reduced pressure on an EYELA N-1001 rotary evaporator. Reactions were monitored by thin-layer chromatography (TLC) on silica gel precoated glass plates (0.2 ± 0.03 mm thickness, GF-254, particle size 0.01–0.04 mm) from Yantai Chemical Industry Research Institute, P. R. China. Chromatograms were visualized by fluorescence quenching with UV light at 254 nm. Flash column chromatography was performed using silica gel (particle size 0.04 – 0.05 mm). ^1H and ^{13}C NMR spectra were recorded in CDCl_3 on Varian Inova (400 MHz and 100 MHz, respectively) spectrometer. ^1H NMR data are reported as follows: chemical shift (δ , ppm), multiplicity (s = singlet, d = doublet, q = quartet, m = multiplet), coupling constants (J) and assignment. Data for ^{13}C NMR are reported in terms of chemical shift (δ , ppm). High-resolution mass spectra (HRMS) for all the compounds were determined on Micromass GCT-TOF mass spectrometer with ESI resource. High performance liquid chromatography (HPLC) was performed on an Agilent 1200 Series chromatographs using a Daicel Chiralpak IA, Chiralpak AD-H or Chiralpak OD-H column (0.46cm x 25 cm). X-ray data were recorded on a Rigaku Mercury CCD/AFC diffractometer. Optical rotations are reported as follows: $[\alpha]_D^{r.t.}$ (c in g per 100 mL, solvent).

2. Optimization of reaction

Table 1. Optimization of Organocatalysts




entry ^a	cat.	time (h)	yield (%) ^b	dr ^c	ee (%) ^d
1	1a	12	73	>20:1	66
2	1b	12	90	>20:1	-93
3	1c	12	50	>20:1	-86
4	1d	12	76	>20:1	38
5	1e	12	90	>20:1	-69
6	1f	12	77	>20:1	-70
7	1g	12	89	>20:1	95

8	1h	12	91	>20:1	99
9	1i	12	83	>20:1	93

^aUnless noted, the reaction was conducted with **5a**(0.12 mmol), **3a**(0.1 mmol) and **cat.** (20 mol %) in toluene (1 mL) at room temperature for 12 h. ^bIsolated yield.

^cDetermined by ¹H NMR. ^dDetermined by chiral HPLC analysis (Chiraldak IA-H).

Table 2. Optimization of the Reaction Conditions



entry ^a	solvent	Cat. 1h (x mol %)	Conc. (mol/L)	yield (%) ^b	dr ^c	ee (%) ^d
1	toluene	20	0.1	91	>20:1	99
2	toluene	10	0.1	76	>20:1	99
3	toluene	5	0.1	50	>20:1	95
4	toluene	2.5	0.1	48	>20:1	70
5	DCM	10	0.1	83	>20:1	98
6	THF	10	0.1	80	>20:1	96
7	CH ₃ CN	10	0.1	79	>20:1	97
8	MTBE	10	0.1	87	>20:1	95
9	DCM	5	0.1	75	>20:1	98
10	DCM	5	0.067	72	>20:1	96
11	DCM	5	0.2	81	>20:1	98

^aUnless noted, the reaction was conducted with **5a** (0.12 mmol), **3a** (0.1 mmol) and **cat.1h** (x mol %) in solvent (1 mL) at room temperature for 12 h. ^bIsolated yield.

^cDetermined by ¹H NMR. ^dDetermined by chiral HPLC analysis (Chiraldak IA-H.)


3. Experimental data

3.1 Synthesis of compounds 4a–4w

General procedure: In an ordinary tube equipped with a magnetic stirring bar, the solution of **2** (0.15 mmol, 1.5 equiv), catalyst **1i** (3.0 mg, 5 mol %, 0.05 equiv) in DCM (1.0 mL) was stirred at –20 °C for 30 min, and then **3** (0.1 mmol, 1 equiv) was added. The reaction was stirred under –20 °C for 40 h, the reaction mixture was directly loaded onto a silica gel and purified by flash chromatography (eluent: petroleum ether/ethyl acetate = 2:1 – 1.5:1) to give desired products **4a**–**4w**.

A specific procedure for synthesis of compound 4a: In an ordinary tube equipped with a magnetic stirring bar, the solution of **2a** (24.3 mg, 0.15 mmol, 1.5 equiv), catalyst **1i** (3.0 mg, 5 mol %, 0.05 equiv) in DCM (1.0 mL) was stirred at –20 °C for 30 min, and then **3a** (25.9 mg, 0.1 mmol, 1 equiv) was added. The reaction was stirred under –20 °C for 40 h, the reaction mixture was directly loaded onto a silica gel and purified by flash chromatography (eluent: petroleum ether/ethyl acetate = 1.5:1) to give desired products **4a**.


Ethyl 2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-*b*] chromene]-2'-carboxylate 4a



yellow solid, melting point: 198–201 °C, 40.9 mg, 97% yield, 98% *ee*, > 20:1 *dr*, $[\alpha]_D^{25} = + 63.0$ (*c* = 0.51, CHCl₃); [Daicel Chiraldak IA, hexane/*i*-PrOH (70:30), flow rate: 1.0 mL·min^{−1}, λ = 254 nm, *t* (major) = 13.936, *t* (minor) = 24.650]; ¹H NMR (400 MHz, CDCl₃) δ 8.83 (s, 0.5H), 8.21 (ddd, *J* = 13.2, 8.0, 1.2 Hz, 1H), 7.89 (d, *J* = 7.6 Hz, 0.5H), 7.54 – 7.49 (m, 1H), 7.45 (td, *J* = 8.0, 1.2 Hz, 0.5H), 7.38 (td, *J* = 8.0, 1.2 Hz, 0.5H), 7.33 – 7.29 (m, 1H), 7.23 – 7.18 (m, 1H), 7.15 – 7.03 (m, 2H), 6.98 (d, *J* = 7.8 Hz, 0.5H), 5.05 (s, 0.5H), 4.42 – 4.32 (dq, *J* = 7.2, 6.8 Hz, 2H), 3.38 (d, *J* = 8.0 Hz, 3H), 3.31 (d, *J* = 14.0 Hz, 0.5H), 3.07 (d, *J* = 14.8 Hz, 0.5H), 2.69 (d, *J* = 14.8 Hz, 0.5H), 2.33 (d, *J* = 14.0 Hz, 0.5H), 1.38 (dt, *J* = 15.8, 7.1 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.71, 175.47, 171.97, 171.84, 168.43, 167.33, 155.05, 154.99, 147.63, 145.48, 143.87, 143.78, 137.11, 136.67, 133.58, 133.44, 130.23, 129.86, 129.54, 128.80, 127.69,


126.32, 126.08, 124.78, 124.77, 124.60, 123.76, 123.74, 123.71, 123.41, 118.07, 117.87, 109.66, 108.61, 94.90, 93.63, 63.71, 62.80, 50.16, 49.56, 37.60, 37.51, 27.41, 27.25, 14.15, 14.08; IR: 3276.4, 2961.7, 1740.5, 1714.4, 1627.4, 1611.0, 1468.6, 1260.0, 1192.0, 1034.8, 1020.7, 796.4, 758.9, 692.5 cm⁻¹; HRMS-ESI calcd. for C₂₃H₁₉NNaO₇ [M+Na]⁺ 444.1054, found: 444.1065.

**Ethyl 2'-hydroxy-1-(methoxymethyl)-2,10'-dioxo-2',3'-dihydro-10'H-spiro
[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4b**



yellow solid, melting point: 141–144 °C, 42.9 mg, 95% yield, 98% ee, > 20:1 dr, $[\alpha]_D^{25} = + 98.0$ (c = 0.50, CHCl₃); [Daicel Chiralpak IA, hexane/i-PrOH (70:30), flow rate: 1.0 mL·min⁻¹, $\lambda = 254$ nm, t (major) = 12.362, t (minor) = 17.090]; ¹H NMR (400 MHz, CDCl₃) δ 8.48 (s, 0.3H), 8.22 (d, *J* = 7.2 Hz, 0.4H), 8.18 (d, *J* = 7.6 Hz, 0.6H), 7.93 (d, *J* = 7.6 Hz, 0.6H), 7.51 – 7.49 (m, 1H), 7.42 (t, *J* = 7.2 Hz, 0.3H), 7.36 (t, *J* = 7.6 Hz, 0.7H), 7.33 – 7.28 (m, 1H), 7.23 (d, *J* = 2.9 Hz, 0.3H), 7.21 – 7.15 (m, 1.2H), 7.11 – 7.04 (m, 1.7H), 5.29 (s, 0.7H), 5.29 (t, *J* = 10.1 Hz, 1H), 5.21 (dd, *J* = 10.8, 5.2 Hz, 1H), 4.36 (dq, *J* = 12.7, 5.7 Hz, 2H), 3.42 (d, *J* = 7.6 Hz, 3H), 3.30 (d, *J* = 13.6 Hz, 0.7H), 3.11 (d, *J* = 14.8 Hz, 0.3H), 2.72 (d, *J* = 14.8 Hz, 0.35H), 2.39 (d, *J* = 14.0 Hz, 0.65H), 1.37 (dt, *J* = 14.2, 7.1 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 178.59, 176.28, 171.92, 171.75, 168.29, 167.22, 155.00, 154.96, 147.42, 145.43, 142.10, 141.90, 136.94, 136.49, 133.73, 133.58, 130.34, 129.65, 129.37, 128.27, 127.82, 126.40, 126.18, 125.12, 124.86, 124.67, 123.90, 123.84, 123.74, 123.70, 117.73, 117.61, 110.10, 110.06, 94.80, 93.64, 72.17, 71.95, 63.68, 62.88, 56.61, 56.37, 50.50, 49.96, 37.78, 37.62, 14.14, 14.07; IR: 3514.9, 3282.1, 2961.4, 2928.7, 1738.7, 1720.6, 1631.9, 1620.9, 1484.3, 1467.9, 1368.6, 1341.2, 1217.1, 1194.4, 1147.4, 1103.9, 1039.2, 977.2, 923.7, 860.6, 775.0, 758.9, 701.2, 660.5, 613.3 cm⁻¹; HRMS-ESI calcd. for C₂₄H₂₂NO₈ [M+H]⁺ 452.1340, found: 452.1348.

Ethyl 1-benzyl-2'-hydroxy-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-




pyrano[3,2-*b*]chromene]-2'-carboxylate 4c

white solid, melting point: 141–144 °C, 48.7 mg, 98%

yield, 99% ee, > 20:1 dr, $[\alpha]_D^{25} = + 114.0$ ($c = 0.50$, CHCl_3); [Daicel Chiraldak IA, hexane/*i*-PrOH (70:30), flow rate: 1.0 $\text{mL}\cdot\text{min}^{-1}$, $\lambda = 254 \text{ nm}$, t (major) = 17.371, t (minor) = 25.698]; ^1H NMR (400 MHz, CDCl_3) δ 8.83 (s, 0.45H), 8.23 (d, $J = 8.0 \text{ Hz}$, 0.45H), 8.18 (d, $J = 8.0 \text{ Hz}$, 0.55H), 7.94 (d, $J = 7.6 \text{ Hz}$, 0.55H), 7.55 – 7.50 (m, 1H), 7.42 – 7.33 (m, 5H), 7.32 – 7.30 (m, 1.5H), 7.23 (d, $J = 8.4 \text{ Hz}$, 1H), 7.12 (t, $J = 7.6 \text{ Hz}$, 0.5H), 7.06 (d, $J = 7.6 \text{ Hz}$, 0.7H), 7.02 (d, $J = 3.2 \text{ Hz}$, 0.5H), 7.00 (d, $J = 4.4 \text{ Hz}$, 0.3H), 6.92 (d, $J = 8.0 \text{ Hz}$, 0.4H), 6.85 (d, $J = 7.6 \text{ Hz}$, 0.5H), 5.33 (s, 0.6H), 5.26 (t, $J = 15.6 \text{ Hz}$, 1H), 4.81 (t, $J = 15.2 \text{ Hz}$, 1H), 4.37 (dq, $J = 7.2, 5.2 \text{ Hz}$, 2H), 3.38 (dd, $J = 14.0, 2.0 \text{ Hz}$, 0.6H), 3.13 (d, $J = 15.2 \text{ Hz}$, 0.4H), 2.76 (d, $J = 14.8 \text{ Hz}$, 0.4H), 2.42 (d, $J = 14.0 \text{ Hz}$, 0.6H), 1.38 (dt, $J = 7.2, 5.2 \text{ Hz}$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 177.95, 175.64, 171.97, 171.81, 168.39, 167.31, 154.00, 154.96, 147.84, 145.80, 136.90, 136.45, 135.44, 134.53, 133.66, 133.48, 130.15, 129.87, 129.44, 129.13, 128.94, 128.71, 128.32, 127.99, 127.78, 127.32, 127.30, 126.37, 126.13, 124.80, 124.70, 124.60, 123.79, 123.75, 123.69, 123.43, 117.76, 117.60, 110.65, 109.59, 94.90, 93.66, 63.64, 62.83, 50.17, 49.55, 44.63, 44.46, 37.42, 37.37, 14.13, 14.07; IR: 3484.2, 3281.4, 2959.1, 2923.7, 1739.1, 1714.4, 1632.2, 1610.4, 1485.9, 1466.6, 1364.0, 1346.3, 1284.3, 1263.4, 1216.9, 1197.6, 1182.2, 1145.9, 1081.0, 1038.4, 974.7, 947.8, 883.8, 808.3, 753.4, 734.7, 698.6, 630.1 cm^{-1} ; HRMS-ESI calcd. for $\text{C}_{29}\text{H}_{24}\text{NO}_7$ $[\text{M}+\text{H}]^+$ 498.1547, found: 498.1545.


Ethyl 1-allyl-2'-hydroxy-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4d



white solid, melting point: 158–160 °C, 43.4 mg, 97% yield, 99% ee, > 20:1 dr, $[\alpha]_D^{25} = + 97.3$ ($c = 0.52$, CHCl_3); [Daicel Chiraldak IA, hexane/*i*-PrOH (70:30), flow rate: 1.0 $\text{mL}\cdot\text{min}^{-1}$, $\lambda = 254 \text{ nm}$, t (major) = 15.593, t (minor) = 19.550]; ^1H NMR (400 MHz, CDCl_3) δ 8.79 (s, 0.45H), 8.21 (dd, $J = 17.2, 7.6 \text{ Hz}$, 1H), 7.93 (d, $J = 7.6 \text{ Hz}$, 0.50H), 7.54 – 7.50 (m, 1H), 7.41 (t, $J = 7.6 \text{ Hz}$, 0.6H), 7.36 – 7.29 (m, 1.4H), 7.25 (d, $J = 7.2 \text{ Hz}$, 0.5H), 7.17 (t, $J = 7.6 \text{ Hz}$, 0.5H), 7.11 – 7.01 (m, 2H), 6.94 (d, $J = 7.6 \text{ Hz}$, 0.5H), 5.99 – 5.88 (m, 1H), 5.34 (dd, $J = 16.8, 10.6 \text{ Hz}$, 2H), 5.21 (s, 0.55H),

4.60 (dd, $J = 16.8$, 3.6 Hz, 1H), 4.36 (dt, $J = 7.6$, 5.6 Hz, 3H), 3.33 (d, $J = 14.0$ Hz, 0.55H), 3.11 (d, $J = 14.8$ Hz, 0.45H), 2.72 (d, $J = 14.8$ Hz, 0.45H), 2.38 (d, $J = 14.0$ Hz, 0.55H), 1.38 (dt, $J = 14.4$, 7.1 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 177.59, 175.22, 171.98, 171.82, 168.42, 167.32, 155.02, 149.97, 147.72, 145.61, 143.07, 142.90, 136.98, 136.52, 133.66, 133.50, 130.76, 130.16, 129.96, 129.83, 129.45, 128.72, 127.78, 126.37, 126.12, 124.80, 124.70, 124.61, 123.82, 123.74, 123.70, 123.37, 118.00, 117.85, 117.68, 117.44, 110.51, 109.49, 94.88, 93.64, 63.69, 62.83, 50.16, 49.53, 43.05, 42.92, 37.50, 37.47, 14.15, 14.08; IR: 3544.6, 3259.4, 2963.1, 2854.3, 1740.2, 1710.8, 1625.9, 1609.6, 1487.0, 1467.4, 1432.8, 1280.3, 1260.9, 1238.1, 1198.6, 1186.3, 1107.0, 1039.8, 1004.7, 977.5, 943.9, 884.7, 855.7, 797.5, 761.9, 702.3, 668.9, 655.5, 636.0, 619.9 cm^{-1} ; HRMS-ESI calcd. for $\text{C}_{25}\text{H}_{22}\text{NO}_7$ $[\text{M}+\text{H}]^+$ 448.1391, found: 448.1393.

1- benzyl 2'-ethyl 2'-hydroxy-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-b]chromene]-1,2'-dicarboxylate 4e




yellow solid, melting point: 196–198 °C, 39.5 mg, 73% yield, 99% ee, $> 20:1$ dr, $[\alpha]_D^{25} = + 98.4$ ($c = 0.50$, CHCl_3); [Daicel Chiralpak IA, hexane/*i*-PrOH (70:30), flow rate: 1.0 $\text{mL}\cdot\text{min}^{-1}$, $\lambda = 254$ nm, t (major) = 28.027, t (minor) = 41.336]; ^1H NMR (400 MHz, CDCl_3) δ 8.82 (s, 0.45H), 8.23 (dd, $J = 14.8$, 7.6 Hz, 1H), 7.93 (d, $J = 7.6$ Hz, 0.55H), 7.54 (t, $J = 7.6$ Hz, 1H), 7.40 – 7.29 (m, 6.45H), 7.23 – 7.01 (m, 3H), 6.92 (d, $J = 7.6$ Hz, 0.5H), 6.85 (d, $J = 7.6$ Hz, 0.5H), 5.27 (t, $J = 15.6$ Hz, 1H), 5.11 (s, 0.55H), 4.82 (t, $J = 14.0$ Hz, 1H), 4.39 (dq, $J = 12.4$, 7.2 Hz, 2H), 3.39 (d, $J = 14.0$ Hz, 0.55H), 3.14 (d, $J = 14.8$ Hz, 0.45H), 2.75 (d, $J = 15.2$ Hz, 0.45H), 2.41 (d, $J = 14.0$ Hz, 0.55H), 1.40 (dt, $J = 12.4$, 7.2 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 178.00, 175.66, 171.99, 171.85, 168.45, 167.34, 155.07, 155.02, 147.80, 143.05, 142.86, 136.95, 136.50, 135.47, 134.56, 133.69, 133.54, 130.18, 129.89, 129.50, 129.18, 128.99, 128.78, 128.38, 128.04, 127.80, 127.37, 127.36, 126.46, 126.22, 124.86, 124.75, 124.67, 123.84, 123.78, 123.47, 117.81, 117.64, 110.66, 109.64, 94.93, 93.64, 63.78, 62.90, 50.21, 49.56, 44.69, 44.52, 37.46, 14.18, 14.12; IR: 3482.3, 3279.6, 2960.8, 2922.9, 1743.1,

1715.8, 1640.6, 1609.8, 1488.3, 1467.7, 1432.2, 1369.4, 1282.4, 1262.1, 1196.7, 1184.7, 1146.1, 1109.0, 1040.2, 1013.5, 972.1, 860.0, 772.8, 753.5, 728.6, 696.9, 630.7 cm⁻¹; HRMS-ESI calcd. for C₃₀H₂₄NO₉ [M+H]⁺ 542.1146, found: 542.1153.

Ethyl 1-acetyl-2'-hydroxy-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4f

yellow solid, melting point: 150–153 °C, 24.2 mg, 54% yield, 98% *ee*, > 20:1 *dr*,




[α]_D²⁵ = + 113.3 (c = 0.30, CHCl₃); [Daicel Chiraldpak IA, hexane/*i*-PrOH (70:30), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 15.747, t (minor) = 20.035]; ¹H NMR (400 MHz, CDCl₃) δ 8.34 (d, *J* = 8.0 Hz, 0.8H), 8.31 (d, *J* = 6.4 Hz, 0.2H), 8.23 – 8.21 (m, 1H), 7.95 (d, *J* = 7.6 Hz, 0.7H), 7.56 (dd, *J* = 7.2, 1.2 Hz, 1H), 7.95 (d, *J* = 2.8 Hz,

0.3H), 7.47 – 7.40 (m, 1H), 7.34 – 7.29 (m, 1.3H), 7.23 (d, *J* = 8.0 Hz, 0.7H), 7.18 (d, *J* = 8.4 Hz, 1H), 7.14 (d, *J* = 8.4 Hz, 0.3H), 5.10 (s, 0.7H), 4.38 (dq, *J* = 15.6, 7.2 Hz, 2H), 3.32 (d, *J* = 14.0 Hz, 0.8H), 3.08 (d, *J* = 15.2 Hz, 0.2H), 2.81 (d, *J* = 15.2 Hz, 0.3H), 2.74 (d, *J* = 5.7 Hz, 3H), 2.47 (d, *J* = 14.0 Hz, 0.7H), 1.38 (dt, *J* = 15.2, 7.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.06, 171.94, 170.71, 168.06, 155.10, 147.08, 140.19, 136.56, 133.94, 133.82, 129.91, 128.76, 127.90, 127.28, 126.85, 126.41, 126.22, 125.96, 125.62, 125.08, 124.91, 123.69, 123.42, 118.05, 117.96, 117.37, 116.65, 94.46, 93.56, 63.93, 63.21, 50.70, 50.51, 38.87, 38.56, 27.35, 27.01, 14.17, 14.13; IR: 3350.2, 2926.9, 2924.5, 1760.2, 1741.5, 1724.4, 1640.9, 1613.6, 1465.6, 1434.8, 1370.1, 1339.0, 1306.9, 1268.1, 1198.3, 1147.9, 1107.9, 1063.4, 973.7, 802.7, 763.4 cm⁻¹; HRMS-ESI calcd. for C₂₄H₂₀NO₈ [M+H]⁺ 450.1183, found: 450.1188.

Ethyl 5-fluoro-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4g

light red solid, melting point: 114–116 °C, 36.0 mg, 82% yield, 99% *ee*, > 20:1 *dr*,


[α]_D²⁵ = + 135.8 (c = 0.46, CHCl₃); [Daicel Chiraldpak IA, hexane/*i*-PrOH (85:15),



flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 30.576]; ¹H NMR (400 MHz, CDCl₃) δ 8.75 (s, 0.3H), 8.22 (dd, *J* = 8.0, 1.6 Hz, 0.3H), 8.18 (dd, *J* = 8.0, 1.6 Hz, 0.7H), 7.69

(dd, $J = 8.4, 2.4$ Hz, 0.7H), 7.55 – 7.50 (m, 1H), 7.34 – 7.27 (m, 1H), 7.13 (dd, $J = 8.8, 2.4$ Hz, 1H), 7.10 – 7.05 (m, 1H), 7.00 – 6.96 (m, 0.7H), 6.89 (dd, $J = 8.4, 4.0$ Hz, 0.7H), 5.28 (d, $J = 2.2$ Hz, 0.7H), 4.36 (m, 2H), 3.35 (dt, $J = 14.4, 7.1$ Hz, 3H), 3.31 (d, $J = 2.4$ Hz, 0.3H), 3.27 (d, $J = 2.4$ Hz, 0.3H), 3.02 (d, $J = 14.8$ Hz, 0.3H), 2.70 (d, $J = 14.8$ Hz, 0.3H), 2.34 (d, $J = 14.0$ Hz, 0.7H), 1.37 (dt, $J = 14.4, 7.1$ Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 177.40, 175.14, 171.96, 171.75, 168.21, 167.19, 160.22 ($J = 243.2$ Hz), 154.50 ($J = 239.6$ Hz), 155.02, 154.09, 147.07, 144.79, 139.79, 139.77, 137.16, 136.60, 133.72, 133.57, 131.23, 131.14, 130.71 ($J = 6.4$ Hz) 130.66 ($J = 6.9$ Hz), 128.94, 126.36, 126.12, 124.90, 124.72, 123.71, 123.68, 118.00, 117.84, 116.75 ($J = 23.6$ Hz), 116.08 ($J = 26.1$ Hz), 115.93 ($J = 23.6$ Hz), 112.15 ($J = 25.4$ Hz), 110.44 ($J = 8.1$ Hz), 109.03 ($J = 8.1$ Hz), 94.79, 93.59, 63.73, 62.89, 50.41 ($J = 1.7$ Hz), 49.86 ($J = 1.6$ Hz), 37.43, 27.58, 27.41, 14.14, 14.07; IR: 3298.6, 2927.8, 1747.9, 1722.8, 1636.2, 1613.7, 1492.8, 1469.3, 1352.8, 1258.6, 1198.5, 1151.0, 1105.5, 1030.8, 972.2, 866.1, 797.3, 734.3, 683.5 cm^{-1} ; HRMS-ESI calcd. for $\text{C}_{23}\text{H}_{19}\text{FNO}_7$ [M+H] $^+$ 440.1140, found: 440.1146.


**Ethyl 5-chloro-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro
[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4h**



yellow solid, melting point: 128–131 °C, 35.0 mg, 77% yield, 94% ee, $> 20:1$ dr, $[\alpha]_D^{25} = + 188.8$ ($c = 0.50$, CHCl_3); [Daicel Chiralpak IA, hexane/*i*-PrOH (85:15), flow rate: 1.0 $\text{mL}\cdot\text{min}^{-1}$, $\lambda = 254$ nm, t (major) = 30.714, t (minor) = 28.046]; ^1H NMR (400 MHz, CDCl_3) δ 8.63 (s, 0.3H), 8.21 (dd, $J = 14.0, 8.0$ Hz, 1H), 7.90 (d, $J = 1.6$ Hz, 0.7H), 7.55 – 7.51 (m, 1H), 7.42 (dd, $J = 8.0, 1.6$ Hz, 0.3H), 7.35 (dd, $J = 8.4, 2.0$ Hz, 0.7H), 7.32 – 7.28 (m, 1H), 7.21 (d, $J = 1.6$ Hz, 0.3H), 7.14 (d, $J = 8.4$ Hz, 0.7H), 7.10 (d, $J = 8.8$ Hz, 0.3H), 6.97 (d, $J = 8.4$ Hz, 0.3H), 6.90 (d, $J = 8.4$ Hz, 0.7H), 5.18 (s, 0.7H), 4.37 (dq, $J = 14.8, 7.2$ Hz, 2H), 3.35 (d, $J = 9.5$ Hz, 3H), 3.28 (d, $J = 14.0$ Hz, 0.7H), 3.03 (d, $J = 14.8$ Hz, 0.3H), 2.69 (d, $J = 14.8$ Hz, 0.3H), 2.33 (d, $J = 14.0$ Hz, 0.7H), 1.37 (dt, $J = 14.8, 7.2$ Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 177.30, 175.04, 171.93, 171.73, 168.17, 167.16, 155.02, 154.96, 146.91, 144.69, 142.39, 137.18, 136.63, 133.73, 133.59,


131.22, 131.04, 130.38, 130.30, 130.25, 129.57, 128.84, 128.26, 126.39, 126.15, 124.92, 124.75, 124.39, 123.71, 118.03, 117.90, 110.64, 109.52, 94.77, 93.55, 63.78, 62.93, 50.18, 49.64, 37.44, 27.57, 27.39, 14.16, 14.09; IR: 3474.2, 2932.3, 1746.1, 1728.2, 1632.8, 1611.2, 1489.4, 1468.1, 1429.9, 1345.7, 1189.4, 1148.1, 1104.3, 1030.5, 977.3, 834.7, 808.9, 762.2, 703.7, 676.4 cm⁻¹; HRMS-ESI calcd. for C₂₃H₁₉ClNO₇ [M+H]⁺ 456.0845, found: 456.0832.

Ethyl 5-bromo-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro [indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4i




white solid, melting point: 124–127 °C, 44.5mg, 89% yield, 93% *ee*, > 20:1 *dr*, [α]_D²⁵ = + 78.6 (c = 0.60, CHCl₃); [Daicel Chiraldpak IA, hexane/*i*-PrOH (80:20), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 22.013, t (minor) = 19.790]; ¹H NMR (400 MHz, CDCl₃) δ 8.61 (s, 0.3H), 8.22 (dd, *J* = 8.0, 1.6 Hz, 0.3H), 8.18 (dd, *J* = 8.0, 1.2 Hz, 0.7H), 8.03 (d, *J* = 1.6 Hz, 0.7H), 7.57 – 7.48 (m, 2H), 7.34 (d, *J* = 2.0 Hz, 0.3H), 7.31 (d, *J* = 8.0 Hz, 0.7H), 7.13 (d, *J* = 8.4 Hz, 0.7H), 7.10 (d, *J* = 8.4 Hz, 0.3H), 6.92 (d, *J* = 8.4 Hz, 0.3H), 6.85 (d, *J* = 8.0 Hz, 0.7H), 5.22 (s, 0.7H), 4.36 (dq, *J* = 14.4, 7.2 Hz, 2H), 3.35 (d, *J* = 9.7 Hz, 3H), 3.29 (d, *J* = 2.0 Hz, 0.3H), 3.26 (d, *J* = 2.4 Hz, 0.35H), 3.03 (d, *J* = 14.8 Hz, 0.35H), 2.68 (d, *J* = 14.8 Hz, 0.3H), 2.33 (d, *J* = 14.0 Hz, 0.7H), 1.36 (dt, *J* = 14.4, 7.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.18, 174.93, 171.91, 171.70, 168.14, 167.15, 154.99, 154.94, 146.89, 144.69, 142.90, 142.87, 137.17, 136.62, 133.72, 133.57, 133.20, 132.46, 131.54, 130.94, 130.66, 127.09, 126.35, 126.12, 124.90, 124.73, 123.72, 123.69, , 118.02, 117.91, 117.38, 116.15, 111.09, 110.03, 94.76, 93.55, 63.75, 62.91, 50.10, 49.56, 37.46, 37.44, 27.54, 27.36, 14.15, 14.08; IR: 3494.2, 3280.2, 2961.3, 1723.3, 1364.5, 1610.4, 1480.4, 1467.2, 1339.7, 1282.0, 1218.4, 1173.6, 1146.4, 1106.2, 1040.3, 977.1, 961.1, 813.5, 797.2, 764.6, 747.7, 669.0, 643.9 cm⁻¹; HRMS-ESI calcd. for C₂₃H₁₉ClNO₇ [M+H]⁺ 500.0339, found: 500.0339.

Ethyl 2'-hydroxy-1,5-dimethyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4j



white solid, melting point: 226–228 °C, 43.0 mg, 99% yield, 96% *ee*, $> 20:1\ dr$, $[\alpha]_D^{25} = + 24.2$ (*c* = 0.50, CHCl₃); [Daicel Chiraldak IA, hexane/*i*-PrOH (80:20), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, *t* (major) = 17.666, *t* (minor) = 15.895]; ¹H NMR (400 MHz, CDCl₃) δ 8.89 (s, 0.5H), 8.22 (dd, *J* = 8.0, 1.6 Hz, 0.5H), 8.18 (dd, *J* = 8.0, 1.6 Hz, 0.5H), 7.69 (s, 0.5H), 7.53 – 7.48 (m, 1H), 7.32 – 7.28 (m, 1H), 7.22 (d, *J* = 8.0 Hz, 0.5H), 7.17 – 7.13 (m, 1H), 7.09 (d, *J* = 8.4 Hz, 0.5H), 7.02 (s, 0.5H), 6.91 (d, *J* = 7.6 Hz, 0.5H), 6.85 (d, *J* = 8.0 Hz, 0.5H), 5.08 (d, *J* = 2.2 Hz, 0.5H), 4.35 (dt, *J* = 7.2, 5.0 Hz, 2H), 3.34 (d, *J* = 8.0 Hz, 3H), 3.29 (dd, *J* = 14.0, 2.4 Hz, 0.5H), 3.04 (d, *J* = 14.8 Hz, 0.5H), 2.66 (d, *J* = 14.8 Hz, 0.5H), 2.31 (d, *J* = 14.0 Hz, 0.5H), 2.30 (d, *J* = 8.8 Hz, 3H), 1.37 (dt, *J* = 16.6, 7.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.59, 175.37, 171.98, 171.84, 168.48, 167.37, 155.04, 154.99, 147.87, 145.70, 141.43, 141.36, 137.05, 136.59, 134.65, 133.52, 133.38, 132.99, 130.47, 129.86, 128.74, 128.73, 128.38, 126.28, 126.03, 124.71, 124.55, 124.47, 123.74, 123.71, 118.11, 117.94, 109.39, 108.30, 94.91, 93.64, 63.66, 62.76, 50.18, 49.61, 37.59, 27.41, 27.25, 21.32, 21.23, 14.14, 14.07; IR: 3494.7, 3282.8, 2961.6, 1745.8, 1718.6, 1636.8, 1611.3, 1499.5, 1359.2, 1282.1, 1260.8, 1196.1, 1103.7, 1037.9, 977.5, 964.8, 811.7, 796.6, 760.2, 699.6, 669.8, 647.7 cm⁻¹; HRMS-ESI calcd. for C₂₄H₂₂NO₇ [M+H]⁺ 436.1391, found: 436.1396.


Ethyl 2'-hydroxy-5-methoxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro [indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4k



white solid, melting point: 191–193 °C, 44.1 mg, 98% yield, 98% *ee*, $> 20:1\ dr$, $[\alpha]_D^{25} = + 141.6$ (*c* = 0.50, CHCl₃); [Daicel Chiraldak IA, hexane/*i*-PrOH (80:20), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, *t* (major) = 22.303, *t* (minor) = 27.639]; ¹H NMR (400 MHz, CDCl₃) δ 8.95 (s, 0.5H), 8.20 – 8.16 (m, 1H), 7.55 (d, *J* = 2.0 Hz, 0.5H), 7.53 – 7.49 (m, 1H), 7.29 (t, *J* = 1.2 Hz, 1H), 7.11 (dd, *J* = 19.6, 8.4 Hz, 1H), 6.93 (s, 1H), 6.89 (d, *J* = 2.4 Hz, 0.5H), 6.84 (d, *J* = 18.8 Hz, 1H), 5.07 (d, *J* = 1.6 Hz, 0.5H), 4.34 (dq, *J* = 15.6, 7.2

Hz, 2H), 3.74 (d, J = 8.0 Hz, 3H), 3.33 (d, J = 7.6 Hz, 3H), 3.28 (d, J = 2.0 Hz, 0.5H), 3.04 (d, J = 14.8 Hz, 0.5H), 2.67 (d, J = 14.8 Hz, 0.5H), 2.32 (d, J = 14.0 Hz, 0.5H), 1.36 (dt, J = 15.6, 7.2 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 177.27, 175.05, 171.92, 171.81, 168.41, 167.37, 157.49, 156.38, 155.02, 154.97, 147.62, 145.52, 137.15, 137.06, 136.99, 136.59, 133.54, 133.42, 130.97, 129.96, 126.24, 126.02, 124.73, 124.57, 123.71, 123.69, 118.08, 117.92, 114.82, 114.58, 114.29, 110.57, 110.22, 108.92, 94.91, 93.60, 63.69, 62.77, 55.95, 55.82, 50.51, 49.89, 37.63, 37.45, 27.47, 27.31, 14.14, 14.06; IR: 3350.6, 2963.2, 2922.7, 1748.1, 1714.7, 1652.5, 1637.1, 1611.6, 1497.2, 147.0, 1363.4, 1339.6, 1260.9, 1236.3, 1202.1, 1160.5, 1144.2, 1108.8, 1039.5, 1025.3, 977.0, 806.5, 758.1, 694.3, 679.9, 646.6 cm^{-1} ; HRMS-ESI calcd. for $\text{C}_{24}\text{H}_{22}\text{NO}_8$ [M+H] $^+$ 452.1340, found: 452.1352.


**Ethyl 6-chloro-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro
[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4l**



yellow solid, melting point: 111–113 °C, 38.3mg, 86% yield, 97% ee, > 20:1 dr, $[\alpha]_D^{25} = + 57.2$ ($c = 0.65$, CHCl_3); [Daicel Chiraldak IA, hexane/*i*-PrOH (80:20), flow rate: 1.0 $\text{mL}\cdot\text{min}^{-1}$, $\lambda = 254 \text{ nm}$, t (major) = 22.883, t (minor) = 30.794]; ^1H NMR (400 MHz, CDCl_3) δ 8.58 (s, 0.3H), 8.22 (dd, J = 8.0, 1.2 Hz, 0.3H), 8.18 (dd, J = 8.0, 1.6 Hz, 0.7H), 7.82 (d, J = 8.0 Hz, 0.7H), 7.55 – 7.51 (m, 1H), 7.34 – 7.28 (m, 1H), 7.15 (d, J = 7.4 Hz, 1.3H), 7.10 (d, J = 8.4 Hz, 0.3H), 7.05 – 7.03 (m, 1H), 6.97 (d, J = 2.0 Hz, 0.7H), 5.19 (s, 0.7H), 4.36 (dq, J = 11.1, 5.6 Hz, 2H), 3.35 (d, J = 9.2 Hz, 3H), 3.27 (d, J = 14.4 Hz, 0.7H), 3.03 (d, J = 14.8 Hz, 0.3H), 2.67 (d, J = 14.8 Hz, 0.3H), 2.31 (d, J = 14.0 Hz, 0.7H), 1.36 (dt, J = 11.1, 5.6 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 177.76, 175.49, 171.96, 171.77, 168.28, 167.21, 155.03, 154.97, 147.06, 145.02, 144.88, 137.15, 136.64, 136.18, 135.45, 133.74, 133.61, 128.85, 128.11, 127.09, 126.39, 126.13, 124.92, 124.81, 123.74, 124.67, 123.73, 123.69, 123.29, 118.03, 117.85, 110.51, 109.38, 94.80, 93.58, 63.79, 62.93, 49.84, 49.25, 37.57, 37.40, 27.56, 27.38, 14.16, 14.09; IR: 3348.8, 3277.2, 2961.0, 2923.4, 1722.4, 1365.8, 1607.2, 1468.0, 1365.6, 1281.9, 1260.5, 1188.7, 1147.4, 1103.4, 1078.4, 1025.5, 971.2, 798.4, 759.1, 645.0,


621.5 cm⁻¹; HRMS-ESI calcd. for C₂₃H₁₉ClNO₇ [M+H]⁺ 456.0845, found: 456.0833.

**Ethyl 6-bromo-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro
[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4m**



light yellow solid, melting point: 105–107 °C, 43.1 mg, 86% yield, 97% *ee*, > 20:1 *dr*, $[\alpha]_D^{25} = + 245.2$ (*c* = 0.25, CHCl₃); [Daicel Chiralpak IA, hexane/*i*-PrOH (80:20), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 22.846, t (minor) = 31.330]; ¹H NMR (400 MHz, CDCl₃) δ 8.57 (s, 0.3H), 8.22 (dd, *J* = 8.0, 1.6 Hz, 0.3H), 8.18 (dd, *J* = 8.0, 1.6 Hz, 0.7H), 7.76 (d, *J* = 8.4 Hz, 0.7H), 7.55 – 7.51 (m, 1H), 7.32 – 7.28 (m, 1.3H), 7.21 (d, *J* = 2.0 Hz, 0.3H), 7.19 (d, *J* = 1.6 Hz, 0.7H), 7.15 (d, *J* = 8.4 Hz, 1H), 7.12 (d, *J* = 1.6 Hz, 0.7H), 7.09 (d, *J* = 1.6 Hz, 0.3H), 5.13 (d, *J* = 2.0 Hz, 0.7H), 4.36 (dt, *J* = 14.4, 7.1 Hz, 2H), 3.35 (d, *J* = 9.3 Hz, 3H), 3.28 (dd, *J* = 14.4, 1.6 Hz, 0.7H), 3.02 (d, *J* = 14.8 Hz, 0.3H), 2.67 (d, *J* = 15.2 Hz, 0.3H), 2.30 (d, *J* = 14.0 Hz, 0.7H), 1.37 (dt, *J* = 14.4, 7.1 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.63, 175.35, 171.89, 171.72, 168.25, 167.19, 155.01, 154.96, 146.91, 145.14, 144.77, 137.16, 136.67, 133.73, 133.60, 129.17, 128.66, 127.69, 1127.61, 126.37, 126.23, 126.13, 125.12, 124.90, 124.73, 123.86, 123.70, 123.30, 118.02, 117.85, 113.27, 112.16, 94.79, 93.55, 63.80, 62.91, 49.89, 49.29, 37.49, 37.34, 27.55, 27.37, 14.15, 14.09; IR: 3396.7, 3280.6, 2961.7, 2924.1, 1723.6, 1636.6, 1602.5, 1468.6, 1365.5, 1282.9, 1260.5, 1188.9, 1149.5, 1101.7, 1025.4, 970.9, 798.9, 759.3, 707.0, 643.9, 620.5 cm⁻¹; HRMS-ESI calcd. for C₂₃H₁₉BrNO₇ [M+H]⁺ 500.0339, found: 500.0346.

**Ethyl 2'-hydroxy-6-methoxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro
[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4n**




light red solid, melting point: 210–211 °C, 33.4 mg, 74% yield, > 99% *ee*, > 20:1 *dr*, $[\alpha]_D^{25} = + 186.0$ (*c* = 0.20, CHCl₃); [Daicel Chiralpak IA, hexane/*i*-PrOH (80:20), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 26.010]; ¹H NMR (400 MHz, CDCl₃) δ 8.77 (s, 0.4H), 8.24 – 8.19 (m, 1H), 7.76 (d, *J* = 8.0 Hz, 0.5H), 7.52 (t, *J* = 7.6 Hz, 1H), 7.30

(dd, $J = 14.4, 7.2$ Hz, 1H), 7.15 (d, $J = 8.4$ Hz, 0.5H), 7.10 (d, $J = 8.4$ Hz, 1H), 6.66 – 6.59 (m, 1H), 6.56 – 6.54 (m, 1H), 4.94 (d, $J = 1.8$ Hz, 0.6H), 4.36 (dd, $J = 14.9, 7.3$ Hz, 2H), 3.86 (d, $J = 7.6$ Hz, 3H), 3.34 (d, $J = 6.0$ Hz, 3H), 3.28 (dd, $J = 14.0, 2.0$ Hz, 0.6H), 3.02 (d, $J = 15.2$ Hz, 0.4H), 2.65 (d, $J = 15.2$ Hz, 0.4H), 2.29 (d, $J = 14.0$ Hz, 0.6H), 1.38 (dd, $J = 14.9, 7.3$ Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 178.34, 176.05, 171.99, 171.89, 168.52, 167.41, 161.64, 161.11, 155.07, 155.03, 147.89, 145.81, 145.16, 136.54, 133.43, 128.53, 126.36, 126.11, 124.75, 124.60, 124.56, 123.76, 121.88, 120.28, 118.11, 117.91, 108.28, 106.82, 97.87, 96.71, 94.98, 93.67, 63.75, 62.82, 55.88, 55.72, 49.74, 49.13, 37.77, 37.68, 27.42, 27.28, 14.18, 14.11; IR: 3334.4, 2962.9, 2938.6, 1740.2, 1707.5, 1629.4, 1612.5, 1470.9, 1456.4, 1373.9, 1288.0, 1262.2, 1194.5, 1149.8, 1101.2, 1062.6, 969.3, 927.7, 877.8, 804.3, 758.7, 691.5, 649.3, 639.4, 617.3 cm^{-1} ; HRMS-ESI calcd. for $\text{C}_{24}\text{H}_{22}\text{NO}_8$ [M+H] $^+$ 452.1340, found: 452.1353

**Ethyl 7-fluoro-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro
[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4o**


yellow solid, melting point: 190–192 °C, 43.5 mg, 99% yield, 99% ee, > 20:1 dr, $[\alpha]_D^{25} = + 132.9$ ($c = 0.54$, CHCl_3); [Daicel Chiralpak IA, hexane/*i*-PrOH (80:20),



flow rate: 1.0 $\text{mL}\cdot\text{min}^{-1}$, $\lambda = 254$ nm, t (major) = 19.841, t (minor) = 40.459]; ^1H NMR (400 MHz, CDCl_3) δ 8.65 (s, 0.4H), 8.21 (dd, $J = 8.0, 1.2$ Hz, 0.4H), 8.17 (dd, $J = 8.0, 1.2$ Hz, 0.6H), 7.71 (d, $J = 7.2$ Hz, 0.6H), 7.55 – 7.50 (m, 1H), 7.33 – 7.28 (m, 1H), 7.18 – 7.16 (m, 1H), 7.14 (d, $J = 2.4$ Hz, 0.4H), 7.12 – 7.07 (m, 1H), 7.02 – 6.97 (m, 1H), 5.20 (s, 0.6H), 4.35 (dq, $J = 14.6, 7.2$ Hz, 2H), 3.56 (d, $J = 2.8$ Hz, 3H), 3.28 (dd, $J = 14.4, 1.6$ Hz, 0.6H), 3.03 (d, $J = 14.8$ Hz, 0.4H), 2.70 (d, $J = 14.8$ Hz, 0.4H), 2.34 (d, $J = 14.0$ Hz, 0.6H), 1.36 (dt, $J = 14.6, 7.2$ Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 177.34, 175.14, 171.93, 171.75, 168.27, 167.19, 155.02, 154.97, 148.02 (d, $J = 244.8$ Hz), 147.84 (d, $J = 242.0$ Hz), 147.11, 137.02, 136.57, 133.71, 136.57, 132.35 (d, $J = 2.5$ Hz), 131.41 (d, $J = 2.7$ Hz), 130.56 (d, $J = 8.4$ Hz), 130.53 (d, $J = 8.8$ Hz), 126.33, 126.08, 125.45 (d, $J = 6.5$ Hz), 124.86, 124.67, 123.84 (d, $J = 8.6$ Hz), 123.68 (d, $J = 4.2$ Hz), 123.58


(d, $J = 3.2$ Hz), 119.65 (d, $J = 3.3$ Hz), 118.28 (d, $J = 19.0$ Hz), 118.03, 117.85, 117.47 (d, $J = 18.8$ Hz), 94.81, 93.54, 63.72, 62.86, 50.33 (d, $J = 1.9$ Hz), 49.69 (d, $J = 2.1$ Hz), 37.76, 37.59, 30.02 (d, $J = 5.8$ Hz), 29.84 (d, $J = 6.2$ Hz), 14.13, 14.06; IR: 3516.5, 3277.3, 2961.2, 2922.7, 1736.5, 1715.6, 1624.6, 1610.9, 1477.8, 1466.6, 1364.9, 1336.3, 1284.1, 1260.1, 1245.1, 1196.8, 1108.1, 1080.2, 1048.3, 1023.4, 988.0, 963.4, 800.7, 758.6, 702.5, 642.4, 628.9 cm^{-1} ; HRMS-ESI calcd. for $\text{C}_{23}\text{H}_{19}\text{FNO}_7$ [M+H]⁺ 440.1140, found: 440.1151.

Ethyl 2'-hydroxy-1,7-dimethyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4p




yellow solid, melting point: 191–194 °C, 43.1 mg, 99% yield, > 99% ee, > 20:1 dr, $[\alpha]_D^{25} = + 92.0$ ($c = 0.50$, CHCl_3); [Daicel Chiraldpak IA, hexane/*i*-PrOH (80:20), flow rate: 1.0 $\text{mL}\cdot\text{min}^{-1}$, $\lambda = 254$ nm, t (major) = 31.735]; ¹H NMR (400 MHz, CDCl_3) δ 8.92 (s, 0.65H), 8.21 (dd, $J = 8.0, 1.2$ Hz, 0.65H), 8.17 (dd, $J = 8.0, 1.6$ Hz, 0.35H), 7.73 (d, $J = 7.2$ Hz, 0.35H), 7.53 – 7.49 (m, 1H), 7.29 (t, $J = 7.2$ Hz, 1H), 7.18 – 7.12 (m, 1.35H), 7.10 – 7.07 (m, 0.35H), 7.05 – 7.02 (m, 1.3H), 6.93 (t, $J = 7.6$ Hz, 0.65H), 5.07 (s, 0.35H), 4.34 (dt, $J = 16.0, 7.2$ Hz, 2H), 3.62 (s, 3H), 3.28 (d, $J = 14.0$ Hz, 0.35H), 2.99 (d, $J = 14.8$ Hz, 0.65H), 2.66 (d, $J = 3.2$ Hz, 3H), 2.62 (d, $J = 14.4$ Hz, 0.65H), 2.30 (d, $J = 14.4$ Hz, 0.35H), 1.36 (dt, $J = 16.0, 7.2$ Hz, 3H); ¹³C NMR (101 MHz, CDCl_3) δ 178.28, 176.32, 171.95, 171.83, 168.44, 167.33, 155.06, 155.00, 147.92, 145.78, 141.50, 141.46, 137.04, 137.64, 133.93, 133.53, 133.38, 133.31, 130.50, 129.38, 126.25, 126.01, 125.51, 124.71, 124.59, 124.55, 123.70, 123.18, 121.64, 121.33, 120.03, 118.10, 117.90, 94.91, 93.63, 63.63, 62.73, 49.61, 49.04, 38.10, 37.95, 30.79, 30.75, 19.40, 19.01, 14.13, 14.05; IR: 3503.2, 3277.8, 2960.2, 2924.9, 1736.6, 1694.9, 1667.7, 1648.6, 1634.0, 1612.0, 1466.3, 1377.1, 1361.1, 1287.1, 1260.5, 1195.2, 1145.4, 1111.1, 1071.5, 1021.2, 965.3, 909.4, 795.5, 763.3, 749.9, 699.7, 643.2, 623.9 cm^{-1} ; HRMS-ESI calcd. for $\text{C}_{24}\text{H}_{22}\text{NO}_7$ [M+H]⁺ 436.1391, found: 436.1400.

Ethyl 2'-hydroxy-1,5,7-trimethyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4q



yellow solid, melting point: 200–202 °C, 35.9 mg, 80% yield, 98% *ee*, > 20:1 *dr*, $[\alpha]_D^{25} = + 45.0$ (*c* = 0.50, CHCl₃); [Daicel Chiraldak IA, hexane/*i*-PrOH (80:20), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 21.379, t (minor) = 19.769]; ¹H NMR (400 MHz, CDCl₃) δ 8.98 (s, 0.7H), 8.22 (dd, *J* = 8.0, 1.6 Hz, 0.7H), 8.18 (dd, *J* = 8.0, 1.6 Hz, 0.3H), 7.54 – 7.50 (m, 1.3H), 7.32 (d, *J* = 0.8 Hz, 0.2H), 7.29 (d, *J* = 8.0 Hz, 0.8H), 7.18 (d, *J* = 8.4 Hz, 0.3H), 7.14 (d, *J* = 8.4 Hz, 0.7H), 6.94 (s, 0.7H), 6.89 (s, 0.3H), 6.82 (s, 0.7H), 5.03 (d, *J* = 2.0 Hz, 0.3H), 4.35 (dq, *J* = 16.8, 7.2 Hz, 2H), 3.59 (s, 3H), 3.27 (dd, *J* = 14.0, 2.4 Hz, 0.3H), 2.98 (d, *J* = 14.8 Hz, 0.7H), 2.63 (d, *J* = 11.2 Hz, 0.6H), 2.62 (s, 3H), 2.29 (d, *J* = 14.4 Hz, 0.4H), 2.23 (d, *J* = 7.2 Hz, 3H), 1.36 (dt, *J* = 16.8, 7.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 178.16, 176.23, 171.99, 171.87, 168.52, 167.41, 155.08, 155.03, 148.16, 146.01, 139.04, 139.00, 137.00, 136.59, 134.37, 133.76, 133.48, 133.35, 132.69, 130.61, 129.42, 126.26, 126.11, 126.01, 124.68, 124.53, 123.74, 122.28, 120.99, 118.17, 117.99, 94.94, 93.64, 63.64, 62.73, 49.67, 49.12, 38.10, 38.06, 30.72, 20.97, 20.88, 19.23, 18.84, 14.14, 14.07; IR: 3151.5, 2961.7, 2921.9, 1757.4, 1710.4, 1660.6, 1632.5, 1612.4, 1485.3, 1468.8, 1442.9, 1371.2, 1287.2, 1260.4, 1200.4, 1139.1, 1099.0, 1077.0, 1025.7, 961.6, 870.6, 800.3, 761.7, 695.9, 648.9 cm⁻¹; HRMS-ESI calcd. for C₂₅H₂₄NO₇ [M+H]⁺ 450.1547, found: 450.1558.

5,6-difluoro-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4r




white solid, melting point: 113–115 °C, 43.9 mg, 96% yield, 93% *ee*, > 20:1 *dr*, $[\alpha]_D^{25} = + 98.2$ (*c* = 0.50, CHCl₃); [Daicel Chiraldak IA, hexane/*i*-PrOH (80:20), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 22.295, t (minor) = 27.049]; ¹H NMR (400 MHz, CDCl₃) δ 8.54 (s, 0.2H), 8.20 (dd, *J* = 8.0, 1.2 Hz, 0.2H), 8.16 (dd, *J* = 8.0, 1.6 Hz, 0.8H), 7.82 (dd, *J* = 10.0, 8.0 Hz, 0.8H), 7.55 – 7.51 (m, 1H), 7.29 (t, *J* = 8.0 Hz, 1H), 7.14 (d, *J* = 8.4 Hz, 0.8H), 7.10 (t, *J* = 8.0 Hz, 0.2H), 6.90 (dd, *J* = 9.2, 6.0 Hz, 0.2H), 6.80 (dd, *J* = 9.6,

6.4 Hz, 1H), 5.51 (s, 0.8H), 4.36 (dq, $J = 13.6, 6.4$ Hz, 2H), 3.34 (d, $J = 10.2$ Hz, 3H), 3.25 (dd, $J = 14.0, 1.6$ Hz, 0.8H), 3.00 (d, $J = 14.8$ Hz, 0.2H), 2.69 (d, $J = 15.2$ Hz, 0.2H), 2.33 (d, $J = 14.4$ Hz, 0.8H), 1.36 (dt, $J = 13.6, 6.4$ Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 17.54, 175.30, 171.96, 171.70, 168.10, 167.14, 154.98, 154.93, 151.39, (d, $J = 248.2$ Hz), 151.25 (d, $J = 248.1$ Hz), 146.83 (d, $J = 241.4$ Hz), 146.76, 146.71 (d, $J = 244.3$ Hz), 140.26 (d, $J = 11.6$ Hz), 137.19, 136.55, 136.55, 133.82, 133.68, 126.38, 126.13, 124.99 (d, $J = 2.9$ Hz), 124.92 (d, $J = 4.0$ Hz), 124.80, 123.68, 123.62, 118.01 (d, $J = 11.7$ Hz), 117.95, 117.83 (d, $J = 42.0$ Hz), 98.90, 98.67, 94.76, 93.61, 63.73, 62.96, 50.06, 49.52, 37.53, 37.41, 27.69, 27.51, 14.12, 14.06; IR: 3279.2, 3070.6, 2961.2, 2161.1, 2031.0, 1979.4, 1626.2, 1613.7, 1506.3, 1428.2, 1391.7, 1368.7, 1283.9, 1252.0, 1185.7, 1152.3, 1096.7, 1024.9, 1007.6, 960.4, 873.5, 786.3, 758.8, 688.3, 645.2, 618.4 cm^{-1} ; HRMS-ESI calcd. for $\text{C}_{23}\text{H}_{18}\text{F}_2\text{NO}_7$ [M+H] $^+$ 458.1046, found: 458.1048.

Methyl 2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4s

light red solid, melting point: 205–207 °C, 39.9 mg, 98% yield, 98% ee, > 20:1 dr, $[\alpha]_D^{25} = +71.5$ ($c = 0.52$, CHCl_3); [Daicel Chiraldak IA, hexane/*i*-PrOH (70:30), flow




rate: 1.0 $\text{mL}\cdot\text{min}^{-1}$, $\lambda = 254$ nm, t (major) = 20.279, t (minor) = 32.183]; ^1H NMR (400 MHz, CDCl_3) δ 8.88 (s, 0.55H), 8.22 (dd, $J = 8.0, 1.2$ Hz, 0.6H), 8.19 (dd, $J = 8.4, 1.6$ Hz, 0.4H), 7.87 (d, $J = 7.6$ Hz, 0.45H), 7.53 – 7.49 (m, 1H), 7.44 (td, $J = 7.6, 1.2$ Hz, 0.6H), 7.38

(dt, $J = 8.0, 1.2$ Hz, 0.4H), 7.33 – 7.29 (m, 1H), 7.20 (dd, $J = 12.0, 6.4$ Hz, 1H), 7.15 – 7.12 (m, 0.55H), 7.09 – 7.06 (m, 1H), 7.04 (d, $J = 8.0$ Hz, 0.6H), 6.97 (d, $J = 7.6$ Hz, 0.4H), 5.01 (d, $J = 2.0$ Hz, 0.45H), 3.91 (s, 3H), 3.37 (d, $J = 10.8$ Hz, 3H), 3.30 (dd, $J = 14.0, 2.4$ Hz, 0.45H), 3.07 (d, $J = 14.8$ Hz, 0.55H), 2.69 (d, $J = 15.2$ Hz, 0.55H), 2.33 (d, $J = 14.0$ Hz, 0.45H); ^{13}C NMR (101 MHz, CDCl_3) δ 177.71, 175.38, 171.94, 171.84, 168.87, 167.82, 155.06, 155.00, 147.64, 145.48, 143.86, 143.00, 137.03, 136.56, 133.62, 133.47, 130.27, 129.82, 129.57, 128.71, 127.64, 126.33, 126.08, 124.81, 124.79, 124.63, 123.75, 123.72, 123.69, 123.43, 118.08, 117.88, 109.69,


108.62, 94.97, 93.72, 54.07, 53.52, 50.15, 49.49, 37.64, 37.48, 27.43, 27.25; IR: 3316.0, 2961.4, 2922.7, 1752.1, 1725.6, 1637.8, 1610.0, 1468.3, 1432.1, 1366.3, 1351.3, 1280.3, 1270.1, 1260.5, 1219.0, 1188.0, 1146.9, 1124.0, 1070.1, 979.7, 966.8, 945.6, 811.9, 801.2, 760.7, 746.8, 660.7, 640.5, 616.8 cm⁻¹; HRMS-ESI calcd. for C₂₂H₁₈NO₇ [M+H]⁺ 408.1078, found: 408.1084.

**Ethyl 8'-fluoro-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro
[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4t**




light red solid, melting point: 170–173 °C, 38.5 mg, 88% yield, 93% ee, > 20:1 dr, [α]_D²⁵ = + 80.2 (c = 0.50, CHCl₃); [Daicel Chiraldak IA, hexane/*i*-PrOH (70:30), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 12.258, t (minor) = 22.094]; ¹H NMR (400 MHz, CDCl₃) δ 8.81 (s, 0.5H), 7.88 (dd, *J* = 7.6, 0.8 Hz, 0.5H), 7.84 (dd, *J* = 8.0, 2.8 Hz, 0.5H), 7.80 (dd, *J* = 8.0, 2.8 Hz, 0.5H), 7.45 (td, *J* = 7.6, 1.2 Hz, 0.5H), 7.38 (td, *J* = 7.6, 1.2 Hz, 0.5H), 7.24 – 7.21 (m, 1.25H), 7.20 – 7.13 (m, 1.25H), 7.11 – 7.06 (m, 1H), 7.04 (d, *J* = 7.6 Hz, 0.5H), 6.97 (d, *J* = 7.6 Hz, 0.5H), 5.17 (s, 0.5H), 4.35 (tq, *J* = 14.4, 7.2 Hz, 2H), 3.36 (d, *J* = 9.6 Hz, 3H), 3.28 (d, *J* = 14.0 Hz, 0.5H), 3.05 (d, *J* = 15.2 Hz, 0.5H), 2.68 (d, *J* = 15.2 Hz, 0.5H), 2.33 (d, *J* = 14.4 Hz, 0.5H), 1.37 (dt, *J* = 14.4, 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 177.58, 175.35, 171.24, 171.11, 168.33, 167.22, 159.24 (*J* = 245.3 Hz), 159.17 (*J* = 245.1 Hz), 151.33, 151.25, 148.05, 145.86, 143.82, 143.73, 136.77, 136.35, 130.33, 129.73, 129.63, 128.63, 127.70, 124.86, 124.84 (*J* = 6.3 Hz), 124.75 (*J* = 4.6 Hz), 123.78, 123.48, 120.06 (*J* = 14.6 Hz), 121.75 (*J* = 14.5 Hz), 120.26 (*J* = 8.1 Hz), 120.06 (*J* = 8.0 Hz), 110.94 (*J* = 27.1 Hz), 110.70 (*J* = 26.9 Hz), 109.72, 108.67, 100.09, 94.97, 93.70, 63.75, 62.86, 50.16, 49.57, 37.64, 37.48, 27.44, 27.27, 14.14, 14.08; IR: 3430.1, 2987.5, 1755.6, 1711.6, 1610.3, 1483.3, 1469.4, 1369.7, 1259.8, 1186.1, 1163.3, 1100.0, 1022.9, 994.4, 852.4, 831.0, 799.5, 757.7, 691.1, 642.2 cm⁻¹; HRMS-ESI calcd. for C₂₃H₁₉FNO₇ [M+H]⁺ 440.1140, found: 440.1143.

**Ethyl 8'-bromo-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro
[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4u**



light red solid, melting point: 136–138 °C, 32.5 mg, 65% yield, 92% *ee*, > 20:1 *dr*, $[\alpha]_D^{25} = + 355.0$ (*c* = 0.61, CHCl₃); [Daicel Chiraldak IA, hexane/*i*-PrOH (70:30), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 15.695, t (minor) = 31.396]; ¹H NMR (400 MHz, CDCl₃) δ 8.82 (s, 0.5H), 8.32 (d, *J* = 2.4 Hz, 0.5H), 8.27 (d, *J* = 2.0 Hz, 0.5H), 7.88 (d, *J* = 7.6 Hz, 0.5H), 7.58 (dt, *J* = 8.8, 2.4 Hz, 1H), 7.47 – 7.36 (m, 1H), 7.24 – 7.18 (m, 1H), 7.10 – 7.04 (m, 1H), 7.03 (d, *J* = 4.8 Hz, 0.5H), 6.99 – 6.96 (m, 1H), 5.22 (s, 0.5H), 4.35 (dq, *J* = 7.2, 4.4 Hz, 2H), 3.36 (d, *J* = 10.0 Hz, 3H), 3.27 (d, *J* = 14.0 Hz, 0.5H), 3.05 (d, *J* = 15.2 Hz, 0.5H), 2.68 (d, *J* = 15.2 Hz, 0.5H), 2.34 (d, *J* = 14.4 Hz, 0.5H), 1.36 (dt, *J* = 14.6, 7.1 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.52, 175.27, 170.73, 170.59, 168.29, 167.18, 153.81, 153.75, 148.11, 145.88, 143.81, 143.71, 137.27, 136.81, 136.58, 136.42, 130.36, 129.65, 128.70, 128.53, 128.46, 127.73, 125.00, 124.98, 124.88, 123.80, 123.51, 120.07, 119.87, 118.24, 118.06, 109.73, 108.67, 95.01, 93.73, 63.75, 62.88, 50.15, 49.57, 37.66, 37.46, 27.45, 27.28, 14.15, 14.08; IR: 3331.6, 2926.6, 1741.1, 1723.1, 1626.8, 1606.3, 1467.2, 1418.4, 1352.2, 1242.0, 1227.8, 1098.5, 1074.8, 987.5, 963.1, 835.7, 754.6, 660.7 cm⁻¹; HRMS-ESI calcd. for C₂₃H₁₉BrNO₇ [M+H]⁺ 500.0339, found: 500.0337.

**Ethyl 2'-hydroxy-1,8'-dimethyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro
[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4v**




yellow solid, melting point: 106–108 °C, 42.2 mg, 97% yield, 98% *ee*, > 20:1 *dr*, $[\alpha]_D^{25} = + 52.8$ (*c* = 0.60, CHCl₃); [Daicel Chiraldak IA, hexane/*i*-PrOH (70:30), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 19.812, t (minor) = 41.106]; ¹H NMR (400 MHz, CDCl₃) δ 8.81 (s, 0.5H), 7.97 (dd, *J* = 18.8, 1.2 Hz, 1H), 7.88 (d, *J* = 7.6 Hz, 0.5H), 7.43 (td, *J* = 8.0, 1.2 Hz, 0.5H), 7.36 (td, *J* = 8.0, 1.2 Hz, 0.5H), 7.32 – 7.29 (m, 1H), 7.21 – 7.14 (m, 1H), 7.07 (dd, *J* = 7.6, 0.8 Hz, 0.5H), 7.02 (d, *J* = 8.4 Hz, 1H), 6.97 (d, *J* = 3.2 Hz, 0.5H), 6.95 (d, *J* = 2.4 Hz, 0.5H), 5.15 (s, 0.5H), 4.39 (dq, *J* = 16.8, 7.2 Hz, 2H), 3.35 (d, *J* = 8.4 Hz, 3H), 3.28 (d, *J* = 14.0 Hz, 0.5H), 3.04 (d, *J* =

14.8 Hz, 0.5H), 2.66 (d, J = 14.8 Hz, 0.5H), 2.36 (d, J = 5.6 Hz, 3H), 2.32 (d, J = 14.0 Hz, 0.5H), 1.36 (dt, J = 16.8, 7.2 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 177.74, 175.52, 172.02, 171.88, 168.45, 167.35, 153.37, 153.30, 147.52, 145.35, 143.84, 143.75, 136.96, 136.51, 134.90, 134.77, 134.74, 134.52, 130.17, 129.93, 129.47, 128.85, 127.68, 125.43, 125.18, 124.73, 123.72, 123.37, 117.79, 117.60, 109.62, 108.56, 94.85, 93.63, 63.62, 62.76, 50.15, 49.56, 37.62, 37.51, 27.38, 27.21, 20.86, 14.13, 14.06; IR: 3283.4, 2936.0, 1717.8, 1611.6, 1488.4, 1471.8, 1368.8, 1278.3, 1191.7, 1161.4, 1129.7, 1031.4, 961.7, 692.2, 662.7 cm^{-1} ; HRMS-ESI calcd. for $\text{C}_{24}\text{H}_{22}\text{NO}_7$ [M+H] $^+$ 436.1391, found: 436.1381.

Ethyl 2'-hydroxy-7'-methoxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4w

yellow solid, melting point: 218–220 °C, 44.6 mg, 99% yield, 99% *ee*, > 20:1 *dr*, $[\alpha]_D^{25} = +43.6$ (c = 0.50, CHCl_3); [Daicel Chiraldak IA, hexane/*i*-PrOH (70:30), flow



rate: 1.0 $\text{mL}\cdot\text{min}^{-1}$, λ = 254 nm, t (major) = 16.022, t (minor) = 23.611]; ^1H NMR (400 MHz, CDCl_3) δ 8.80 (s, 0.5H), 8.11 (d, J = 9.2 Hz, 0.5H), 8.05 (d, J = 8.8 Hz, 0.5H), 7.92 (d, J = 7.2 Hz, 0.5H), 7.45 (t, J = 8.4 Hz, 0.5H), 7.39 (t, J =


7.2 Hz, 0.5H), 7.24 – 7.17 (m, 1H), 7.11 – 7.04 (m, 1H), 6.98 (d, J = 8.0 Hz, 0.5H), 6.85 (ddd, J = 15.6, 8.8, 2.0 Hz, 1H), 6.49 (d, J = 2.4 Hz, 0.5H), 6.44 (d, J = 2.0 Hz, 0.5H), 5.41 (s, 0.5H), 4.36 (q, J = 7.2 Hz, 2H), 3.77 (s, 3H), 3.37 (d, J = 8.0 Hz, 3H), 3.25 (d, J = 14.0 Hz, 0.5H), 3.04 (d, J = 14.8 Hz, 0.5H), 2.67 (d, J = 14.8 Hz, 0.5H), 2.34 (d, J = 14.0 Hz, 0.5H), 1.37 (dt, J = 16.9, 7.1 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 177.74, 175.61, 171.50, 171.27, 168.44, 167.36, 164.14, 164.03, , 156.86, 156.77, 147.09, 144.90, 143.83, 143.73, 137.00, 136.50, 130.16, 129.94, 129.44, 128.86, 127.77, 127.58, 127.27, 124.75, 123.76, 123.40, 117.60, 117.49, 114.60, 114.49, 109.65, 108.65, 99.92, 94.86, 93.72, 63.52, 62.76, 55.89, 55.85, 50.07, 49.53, 37.76, 37.60, 27.40, 27.24, 14.12, 14.05; IR: 3287.6, 2962.2, 1733.3, 1609.8, 1446.5, 1422.9, 1368.4, 1265.9, 1167.8, 1153.7, 1100.4, 1028.0, 973.5, 833.4, 748.5, 694.1, 635.9 cm^{-1} ; HRMS-ESI calcd. for $\text{C}_{24}\text{H}_{22}\text{NO}_8$ [M+H] $^+$ 452.1340, found: 452.1343.

3.2 Synthesis of compounds 6a–6t

General procedure: In an ordinary tube equipped with a magnetic stirring bar, the solution of **5** (0.12 mmol, 1.2 equiv), catalyst **1h** (2.5 mg, 5 mol %, 0.05 equiv) in DCM (0.5 mL) was stirred at rt. for 30 min, and then **3** (0.1 mmol, 1 equiv) was added. The reaction was stirred under rt. for 12 h, the reaction mixture was directly loaded onto a silica gel and purified by flash chromatography (eluent: petroleum ether/DCM = 1:1 – 0:1) to give desired products **6a–6t**.

A specific procedure for synthesis of compound 6a: In an ordinary tube equipped with a magnetic stirring bar, the solution of **5a** (20.9 mg, 0.15 mmol, 1.5 equiv), catalyst **1h** (2.5 mg, 5 mol %, 0.05 equiv) in DCM (0.5 mL) was stirred at rt. for 30 min, and then **3a** (25.9 mg, 0.1 mmol, 1 equiv) was added. The reaction was stirred under rt. for 40 h, the reaction mixture was directly loaded onto a silica gel and purified by flash chromatography (eluent: petroleum ether/ethyl acetate = 1.5:1) to give desired products **6a**.


Ethyl-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate **6a**



foamy solid, 35.1 mg, 81% yield; 98% *ee*, > 20/1 *dr*, $[\alpha]_D^{26}$ = - 36.01 (*c* = 1.43, CH₂Cl₂); [Daicel Chiraldak IA, hexane/i-PrOH (75:25), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 17.981, t (minor) = 22.054]; ¹H (400 Hz, CDCl₃): δ 9.17 (s, 0.6H), 8.13 – 8.07 (m, 1H), 7.87 – 7.81 (m, 1H), 7.70 – 7.59 (m, 3H), 7.38 – 7.29 (m, 1H), 7.10 – 7.05 (m, 1H), 7.01 – 6.94 (m, 1H), 5.29 (s, 0.4H), 4.37 (q, *J* = 8.0 Hz, 2H), 3.39 (s, 1.85H), 3.38 (s, 1.15H), 3.03 (dd, *J* = 8.0, 4.0 Hz, 0.35H), 2.80 (d, *J* = 16.0 Hz, 0.65H), 2.56 (d, *J* = 16.0 Hz, 0.65H), 2.17 (d, *J* = 16.0 Hz, 0.35H), 1.38 (t, *J* = 8.0 Hz, 1.8H), 1.35 (t, *J* = 8.0 Hz, 1.2H); ¹³C NMR (101 MHz, CDCl₃) δ 182.36, 179.70, 178.88, 178.66, 178.53, 168.29, 166.81, 155.24, 154.13, 143.94, 143.83, 134.47, 134.40, 133.78, 133.61, 132.08, 131.55, 131.50, 130.93, 130.87, 129.62, 128.85, 126.82, 126.69, 126.62, 126.53, 124.22, 122.36, 122.26, 121.75, 120.83, 109.42, 108.50, 97.10, 95.12, 64.15, 63.00, 46.82, 45.59, 37.46, 36.72, 27.24, 27.17, 14.16, 14.07; IR: 3431.3, 1751.2,


1714.3, 1682.4, 1611.4, 1384.3, 1273.2, 1140.0, 1047.0, 974.3, 755.5, 723.2, 684.6, 543.0, 416.1 cm^{-1} ; HRMS-ESI: calcd. for $\text{C}_{24}\text{H}_{20}\text{NO}_7$ $[\text{M}+\text{H}]^+$ 434.1234, found: 434.1241.

Ethyl-2-hydroxy-1'-(methoxymethyl)-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6b



foamy solid, 31.0 mg, 67% yield; 97% *ee*, $> 20/1$ *dr*, $[\alpha]_D^{26} = -15.84$ ($c = 1.19$, CH_2Cl_2); [Daicel Chiraldak OD-H, hexane/*i*-PrOH (70:30), flow rate: 1.0 $\text{mL}\cdot\text{min}^{-1}$, $\lambda = 254$ nm, t (major) = 16.117, t (minor) = 7.124]; ^1H (400 Hz, CDCl_3): δ 8.83 (s, 0.6H), 8.14 – 8.07 (m, 1H), 7.88 – 7.83 (m, 1H), 7.71 – 7.69 (m, 0.5H), 7.68 – 7.62 (m, 2H), 7.38 – 7.28 (m, 1H), 7.22 – 7.15 (m, 1H), 7.12 – 7.07 (m, 1H), 7.02 – 6.98 (m, 0.5H), 5.32 (s, 0.4H), 5.30 – 5.22 (m, 2H), 4.37 (q, $J = 8.0$ Hz, 2H), 3.52 (s, 1.4H), 3.49 (s, 1.6H), 3.02 (d, $J = 16.0$ Hz, 0.5H), 2.82 (d, $J = 16.0$ Hz, 0.5H), 2.58 (d, $J = 16.0$ Hz, 0.55H), 2.22 (d, $J = 16.0$ Hz, 0.45H), 1.39 (t, $J = 8.0$ Hz, 1.55H), 1.35 (t, $J = 8.0$ Hz, 1.45H); ^{13}C NMR (101 MHz, CDCl_3): δ 182.34, 182.25, 180.72, 179.18, 178.86, 178.58, 168.17, 166.69, 155.19, 154.16, 142.19, 142.13, 134.51, 134.44, 133.84, 133.65, 131.60, 131.53, 131.52, 131.05, 130.94, 130.87, 129.49, 128.93, 126.91, 126.86, 126.75, 126.65, 126.63, 124.61, 122.82, 122.33, 121.64, 120.76, 110.86, 109.94, 96.95, 95.16, 72.41, 72.30, 64.18, 63.09, 57.05, 56.78, 47.11, 45.99, 37.93, 37.08, 14.15, 14.08; IR: 3411.4, 2935.3, 1750.6, 1722.1, 1684.0, 1655.7, 1594.9, 1467.8, 1300.9, 1202.5, 1133.1, 1044.3, 975.6, 952.3, 756.3, 724.5, 684.1 cm^{-1} ; HRMS-ESI: calcd. for $\text{C}_{25}\text{H}_{22}\text{NNaO}_8$ $[\text{M}+\text{H}]^+$ 486.1159, found: 464.1148.


Ethyl-1'-benzyl-2-hydroxy-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6c



foamy solid, 26.5 mg, 52% yield; 97% *ee*, $> 20/1$ *dr*, $[\alpha]_D^{26} = -27.12$ ($c = 2.05$, CH_2Cl_2); [Daicel Chiraldak IA, hexane/*i*-PrOH (70:30), flow rate: 1.0 $\text{mL}\cdot\text{min}^{-1}$, $\lambda = 254$ nm, t (major) = 26.256, t (minor) = 24.481]; ^1H (400 Hz, CDCl_3): δ 9.14 (s, 0.6H), 8.16 – 8.08 (m, 1H), 7.94 – 7.85


(m, 1H), 7.72 – 7.69 (m, 0.4H), 7.68 – 7.64 (m, 2H), 7.49 – 7.46 (m, 2H), 7.41 – 7.36 (m, 2H), 7.34 – 7.28 (m, 1H), 7.25 – 7.15 (m, 1H), 7.08 – 7.06 (m, 0.6H), 7.05 – 6.92 (m, 1H), 6.87 – 6.77 (m, 1H), 5.29 (s, 0.4H), 5.18 – 5.00 (m, 2H), 4.39 (q, J = 8.0 Hz, 2H), 3.12 – 3.08 (m, 0.4H), 2.85 (d, J = 16.0 Hz, 0.6H), 2.59 (d, J = 16.0 Hz, 0.6H), 2.24 (d, J = 16.0 Hz, 0.4H), 1.40 (t, J = 8.0 Hz, 1.8H), 1.37 (t, J = 8.0 Hz, 1.2H); ^{13}C NMR (101 MHz, CDCl_3): 182.26, 180.01, 178.89, 178.65, 178.63, 168.26, 166.80, 155.29, 154.24, 143.01, 142.92, 135.87, 134.86, 134.48, 134.41, 133.78, 133.62, 132.18, 131.57, 131.48, 130.94, 130.89, 129.22, 129.11, 128.93, 128.68, 128.10, 127.70, 127.49, 127.36, 126.84, 126.81, 126.78, 126.66, 126.62, 124.24, 122.34, 122.26, 121.67, 120.71, 110.51, 109.65, 97.08, 95.18, 64.21, 63.06, 46.85, 45.71, 44.90, 44.67, 37.79, 37.06, 14.17, 14.09; IR: 3415.8, 2983.5, 1750.6, 1712.6, 1682.6, 1655.3, 1357.6, 1333.3, 1221.7, 1155.1, 1027.7, 949.1, 855.9, 830.0, 793.1, 754.0, 723.3, 697.2, 476.4 cm^{-1} ; HRMS-ESI: calcd. for $\text{C}_{30}\text{H}_{24}\text{NO}_7$ [M+H] $^+$ 510.1547, found: 510.1562.

Ethyl-1'-allyl-2-hydroxy-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6d




122.29, 121.72, 120.76, 118.62, 117.90, 110.33, 109.49, 97.06, 95.13, 64.18, 63.03, 46.81, 45.62, 43.32, 43.20, 37.68, 36.95, 14.16, 14.08; IR: 3412.3, 2984.3, 2925.6, 1750.3, 1655.8, 1435.0, 1333.2, 1271.9, 1201.5, 1046.3, 969.1, 948.1, 793.0, 755.3, 724.0, 683.9 cm⁻¹; HRMS-ESI: calcd. for C₂₆H₂₂NO₇ [M+H]⁺ 460.1391, found: 460.1404.

1'-benzyl-2-ethyl-2-hydroxy-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-1',2-dicarboxylate 6e



foamy solid, 32.7 mg, 59% yield; 97% ee, > 20/1 dr, [α]_D²⁶ = - 29.64 (c = 1.28, CH₂Cl₂); [Daicel Chiraldak IA, hexane/i-PrOH (70:30), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 26.872, t (minor) = 24.448]; ¹H (400 Hz, CDCl₃): δ 9.14 (s, 0.6H), 8.14 – 8.08 (m, 1H), 7.91 – 7.86 (m, 1H), 7.71 – 7.64 (m, 2.45H), 7.48 – 7.45 (m, 2H), 7.41 – 7.36 (m, 2H), 7.34 – 7.28 (m, 1H), 7.25 – 7.15 (m, 1H), 7.08 – 7.06 (m, 0.55H), 7.05 – 6.91 (m, 1H), 6.87 – 6.77 (m, 1H), 5.19 (s, 0.4H), 5.16 – 5.00 (m, 2H), 4.38 (q, J = 8.0 Hz, 2H), 3.09 (d, J = 16.0 Hz, 0.4H), 2.84 (d, J = 16.0 Hz, 0.6H), 2.59 (d, J = 16.0 Hz, 0.6H), 2.24 (d, J = 16.0 Hz, 0.4H), 1.42 – 1.35 (m, 3H); ¹³C NMR (101 MHz, CDCl₃): δ 182.26, 180.01, 178.90, 178.66, 178.63, 168.27, 166.80, 155.29, 154.25, 143.01, 142.92, 135.88, 134.87, 134.48, 134.41, 133.79, 133.62, 132.18, 131.57, 131.49, 130.95, 130.89, 129.22, 129.11, 128.93, 128.69, 128.10, 127.71, 127.49, 127.36, 126.84, 126.82, 126.79, 126.66, 126.62, 124.24, 122.35, 122.26, 121.67, 120.71, 110.51, 109.66, 97.08, 95.19, 64.21, 63.07, 46.85, 45.72, 44.91, 44.67, 37.80, 37.07, 14.17, 14.09; IR: 3415.8, 2925.4, 2853.2, 1750.3, 1712.9, 1682.3, 1271.1, 1155.0, 1046.5, 1027.7, 1011.3, 948.2, 830.1, 753.8, 723.2, 697.4, 553.1, 455.2 cm⁻¹; HRMS-ESI: calcd. for C₃₁H₂₄NO₉ [M+H]⁺ 554.1446, found: 554.1426.


Ethyl-1'-acetyl-2-hydroxy-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6f



foamy solid, 25.8 mg, 56% yield; 97% ee, > 20/1 dr, [α]_D²⁶ = - 3.82 (c = 1.02, CH₂Cl₂); [Daicel Chiraldak IA, hexane/i-PrOH (70:30), flow rate: 1.0 mL·min⁻¹, λ = 254

nm, t (major) = 14.311, t (minor) = 12.719]; ^1H (400 Hz, CDCl_3): δ 8.34 – 8.29 (m, 1H), 8.15 – 8.10 (m, 1H), 7.89 – 7.84 (m, 1.2H), 7.73 – 7.65 (m, 2.8H), 7.40 – 7.32 (m, 1H), 7.18 – 7.08 (m, 1.3H), 5.25 (s, 0.7H), 4.42 – 4.36 (m, 2H), 3.00 (d, J = 16.0 Hz, 0.7H), 2.83 (d, J = 16.0 Hz, 0.3H), 2.74 (s, 2.2H), 2.73 (s, 1H), 2.32 (d, J = 16.0 Hz, 0.8H), 1.41 – 1.36 (m, 3H); ^{13}C NMR (101 MHz, CDCl_3): δ 182.37, 179.55, 178.69, 171.05, 167.93, 154.14, 140.11, 134.69, 134.64, 134.12, 133.92, 131.32, 131.28, 130.84, 130.28, 129.76, 129.19, 127.02, 126.84, 126.72, 126.49, 126.29, 124.87, 122.04, 121.70, 117.25, 116.59, 96.54, 95.11, 64.38, 63.34, 46.34, 38.73, 37.45, 26.98, 14.16, 14.11; IR: 3416.5, 2985.1, 1753.6, 1713.9, 1654.5, 1594.9, 1580.1, 1336.1, 1272.4, 1227.5, 1040.9, 956.1, 917.2, 830.1, 794.2, 721.1, 684.6, 530.5 cm^{-1} ; HRMS-ESI: $^+ \text{calcd. for C}_{25}\text{H}_{20}\text{NO}_8 [\text{M}+\text{H}]$ 462.1183, found: 462.1196.


Ethyl-5'-fluoro-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6g



foamy solid, 31.5 mg, 70% yield; 97% ee, $> 20/1 dr$, $[\alpha]_D^{26}$ = – 14.28 (c = 1.08, CH_2Cl_2); [Daicel Chiraldak IA, hexane/*i*-PrOH (70:30), flow rate: 1.0 $\text{mL}\cdot\text{min}^{-1}$, λ = 254 nm, t (major) = 13.975, t (minor) = 10.650]; ^1H (400 Hz, CDCl_3): δ 9.12 (s, 0.55H), 8.17 – 8.10 (m, 1H), 7.91 – 7.85 (m, 1H), 7.74 – 7.65 (m, 2H), 7.48 – 7.45 (m, 0.55H), 7.11 – 7.01 (m, 1H), 6.97 – 6.94 (m, 0.45H), 6.90 – 6.84 (m, 1H), 5.24 (s, 0.45H), 4.40 (q, J = 8.0 Hz, 2H), 3.40 (s, 1.4H), 3.38 (s, 1.6H), 3.05 (d, J = 16.0 Hz, 0.5H), 2.78 (d, J = 16.0 Hz, 0.5H), 2.59 (d, J = 16.0 Hz, 0.5H), 2.19 (d, J = 16.0 Hz, 0.5H), 1.42 (t, J = 8.0 Hz, 1.3H), 1.38 (t, J = 8.0 Hz, 1.7H); ^{13}C NMR (101 MHz, CDCl_3): δ 182.41, 182.36, 179.43, 178.75, 178.50, 178.21, 168.08, 166.67, 160.03 (J = 242 Hz), 158.89 (J = 267 Hz), 155.40, 154.20, 140.01, 140.00, 139.77, 139.75, 134.55 (J = 8 Hz), 133.94, 133.76, 131.48, 130.90 (J = 6 Hz), 126.94, 126.72 (J = 1 Hz), 126.56, 121.38, 121.31, 120.23, 115.61 (J = 24 Hz), 115.23 (J = 25 Hz), 115.06 (J = 24 Hz), 110.84, 110.59, 110.08, 110.00, 108.81, 108.72, 97.03, 95.03, 64.25, 63.11, 47.08, 45.90, 37.29, 36.55, 27.41, 27.34, 14.17, 14.08; IR: 3424.4, 2926.6, 1750.7, 1714.4, 1683.0, 1656.5, 1620.2, 1594.0, 1333.5, 1269.3, 1119.0, 959.6, 920.2, 876.6, 817.2, 720.7, 622.7, 502.3 cm^{-1} ; HRMS-


ESI: calcd. for $C_{24}H_{19}FNO_7$ [M+H]⁺ 452.1140, found: 452.1136.

Ethyl-5'-chloro-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6h



foamy solid, 41.1 mg, 88% yield; 97% *ee*, > 20/1 *dr*, $[\alpha]_D^{26} = -22.49$ (*c* = 1.44, CH₂Cl₂); [Daicel Chiraldak IA, hexane/*i*-PrOH (70:30), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 14.660, t (minor) = 8.947]; ¹H (400 Hz, CDCl₃): δ 8.99 (s, 0.4H), 8.15 – 8.08 (m, 1H), 7.88 – 7.83 (m, 1H), 7.73 – 7.70 (m, 0.5H), 7.69 – 7.64 (m, 2H), 7.35 – 7.27 (m, 1.2H), 7.06 – 7.05 (m, 0.5H), 6.95 – 6.87 (m, 1H), 5.32 (s, 0.4H), 4.38 (q, *J* = 8.0 Hz, 2H), 3.38 (s, 1.4H), 3.36 (s, 1.6H), 3.01 (d, *J* = 16.0 Hz, 0.55H), 2.77 (d, *J* = 16.0 Hz, 0.45H), 2.57 (d, *J* = 16.0 Hz, 0.45H), 2.18 (d, *J* = 16.0 Hz, 0.55H), 1.40 (t, *J* = 8.0 Hz, 1.4H), 1.35 (t, *J* = 8.0 Hz, 1.6H); ¹³C NMR (101 MHz, CDCl₃): δ 182.35, 179.56, 178.93, 178.69, 178.44, 168.31, 166.85, 155.18, 154.06, 141.52, 141.37, 134.43, 134.36, 133.95, 133.73, 133.55, 132.04, 131.77, 131.55, 130.92, 130.85, 129.58, 129.09, 127.61, 126.77, 126.71, 126.56, 123.09, 121.88, 120.94, 109.13, 108.18, 97.10, 95.16, 64.06, 62.96, 46.83, 45.67, 37.56, 36.77, 27.24, 27.17, 21.31, 21.23, 14.14, 14.05; IR: 3431.7, 2926.0, 1751.0, 1718.9, 1683.4, 1654.9, 1384.3, 1106.2, 989.3, 976.4, 728.9, 630.6, 518.5, 475.2, 416.8 cm⁻¹; HRMS-ESI: calcd. for C₂₄H₁₉ClNO₇ [M+H]⁺ 468.0845, found: 468.0842.


Ethyl-5'-bromo-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6i



foamy solid, 47.1 mg, 92% yield; 97% *ee*, > 20/1 *dr*, $[\alpha]_D^{26} = -27.45$ (*c* = 1.51, CH₂Cl₂); [Daicel Chiraldak IA, hexane/*i*-PrOH (70:30), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 15.113, t (minor) = 9.027]; ¹H (400 Hz, CDCl₃): δ 8.95 (s, 0.5H), 8.12 – 8.05 (m, 1H), 7.86 – 7.81 (m, 1H), 7.78 – 7.77 (m, 0.55H), 7.69 – 7.64 (m, 2H), 7.48 – 7.40 (m, 1H), 7.18 – 7.17 (m, 0.45H), 6.89 – 6.81 (m, 1H), 5.40 (s, 0.5H), 4.39 – 4.33 (m, 2H), 3.36 (s, 1.3H), 3.34 (s, 1.7H), 2.98 (d, *J* = 16.0 Hz, 0.6H), 2.76 (d, *J* = 16.0 Hz, 0.4H), 2.56 (d,


J = 16.0 Hz, 0.4H), 2.17 (d, *J* = 16.0 Hz, 0.6H), 1.38 (t, *J* = 8.0 Hz, 1.3H), 1.33 (t, *J* = 8.0 Hz, 1.7H); ¹³C NMR (101 MHz, CDCl₃): δ 182.36, 182.32, 179.18, 178.69, 178.41, 177.97, 167.94, 166.60, 155.32, 154.19, 143.05, 142.87, 134.56, 134.47, 133.99, 133.91, 133.72, 133.33, 132.17, 131.59, 131.40, 131.38, 130.87, 130.79, 130.05, 126.88, 126.67, 126.66, 126.57, 125.58, 121.16, 120.13, 116.73, 115.10, 110.80, 109.86, 96.93, 95.06, 64.12, 63.10, 46.73, 45.61, 37.24, 36.56, 27.32, 27.24, 14.12, 14.04.; IR: 3440.0, 2924.8, 1718.1, 1682.4, 1654.7, 1621.9, 1465.7, 1332.3, 1202.3, 1105.0, 975.7, 953.8, 797.1, 724.8, 689.4, 614.8, 538.8, 418.6 cm⁻¹; HRMS-ESI: calcd. for C₂₄H₁₉BrNO₇ [M+H]⁺ 512.0339, found: 512.0328.

Ethyl-2-hydroxy-1',5'-dimethyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6j




foamy solid, 38.9 mg, 87% yield; 97% ee, > 20/1 *dr*, [α]_D²⁶ = -50.50 (c = 1.67, CH₂Cl₂); [Daicel Chiraldak IA, hexane/i-PrOH (70:30), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 11.020, t (minor) = 7.396]; ¹H (400 Hz, CDCl₃): δ 9.23 (s, 0.7H), 8.12 – 8.06 (m, 1H), 7.86 – 7.82 (m, 1H), 7.69 – 7.62 (m, 2H), 7.15 – 7.09 (m, 1H), 6.90 – 6.83 (m, 2H), 5.29 (s, 0.3H), 4.37 (q, *J* = 8.0 Hz, 2H), 3.36 (s, 2H), 3.35 (s, 1H), 3.01 (d, *J* = 16.0 Hz, 0.3H), 2.78 (d, *J* = 16.0 Hz, 0.7H), 2.54 (d, *J* = 16.0 Hz, 0.7H), 2.26 (s, 2H), 2.25 (s, 1H), 2.16 (d, *J* = 16.0 Hz, 0.3H), 1.38 (t, *J* = 8.0 Hz, 2H), 1.34 (t, *J* = 8.0 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃): δ 182.40, 182.36, 179.32, 178.75, 178.46, 178.10, 168.01, 166.63, 155.37, 154.22, 142.60, 142.40, 134.59, 134.51, 133.95, 133.77, 133.72, 132.98, 131.45, 131.43, 130.92, 130.85, 129.56, 129.31, 128.74, 127.77, 127.40, 126.94, 126.73, 126.70, 126.60, 122.90, 121.23, 120.18, 110.34, 109.35, 96.97, 95.05, 64.21, 63.13, 46.84, 45.69, 37.27, 36.56, 27.38, 27.30, 14.16, 14.07; IR: 3410.4, 2925.3, 1749.9, 1721.9, 1682.4, 1618.5, 1333.2, 1271.5, 1104.2, 976.8, 913.2, 871.4, 721.3, 628.8, 530.1, 470.1 cm⁻¹; HRMS-ESI: calcd. for C₂₅H₂₂NO₇ [M+H]⁺ 448.1391, found: 448.1382.

Ethyl-2-hydroxy-5'-methoxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6k



foamy solid, 33.3 mg, 72% yield; 97% *ee*, > 20/1 *dr*, $[\alpha]_D^{26} = -37.09$ (*c* = 1.41, CH₂Cl₂); [Daicel Chiraldak IA, hexane/i-PrOH (70:30), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 13.584, t (minor) = 11.840]; ¹H (400 Hz, CDCl₃): δ 9.29 (s, 0.6H), 8.13 – 8.06 (m, 1H), 7.88 – 7.82 (m, 1H), 7.70 – 7.61 (m, 2H), 7.32 – 7.31 (m, 0.3H), 6.92 – 6.83 (m, 2H), 6.67 – 6.66 (m, 0.7H), 5.21 (s, 0.4H), 4.37 (q, *J* = 8.0 Hz, 2H), 3.72 (s, 2H), 3.71 (s, 1H), 3.36 (s, 2H), 3.35 (s, 1H), 3.03 (d, *J* = 16.0 Hz, 0.3H), 2.77 (d, *J* = 16.0 Hz, 0.7H), 2.56 (d, *J* = 16.0 Hz, 0.65H), 2.17 (d, *J* = 16.0 Hz, 0.35H), 1.38 (t, *J* = 8.0 Hz, 2H), 1.34 (t, *J* = 8.0 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃): δ 182.40, 182.34, 179.26, 178.90, 178.70, 178.13, 168.29, 166.86, 157.12, 155.65, 155.26, 154.10, 137.48, 137.08, 134.48, 134.41, 133.78, 133.62, 133.41, 132.82, 131.56, 130.94, 130.87, 126.82, 126.71, 126.62, 126.57, 120.80, 114.43, 113.32, 113.09, 109.84, 109.73, 108.65, 97.14, 95.12, 64.17, 63.01, 55.86, 55.80, 47.15, 45.95, 37.60, 36.63, 27.32, 27.26, 14.16, 14.07; IR: 3427.6, 2937.4, 1751.1, 1710.3, 1682.1, 1656.3, 1618.4, 1579.5, 1273.2, 1156.4, 976.7, 956.2, 872.1, 800.3, 760.2, 721.0, 693.9, 529.9 cm⁻¹; HRMS-ESI: calcd. for C₂₅H₂₂NO₈ [M+H]⁺ 464.1340, found: 464.1326.


Ethyl-6'-chloro-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6l



foamy solid, 32.3 mg, 69% yield; 97% *ee*, > 20/1 *dr*, $[\alpha]_D^{26} = -6.56$ (*c* = 1.70, CH₂Cl₂); [Daicel Chiraldak IA, hexane/i-PrOH (80:20), flow rate: 1.0 mL·min⁻¹, λ = 210 nm, t (major) = 34.813, t (minor) = 32.136]; ¹H (400 Hz, CDCl₃): δ 8.93 (s, 0.4H), 8.12 – 8.05 (m, 1H), 7.87 – 7.81 (m, 1H), 7.71 – 7.62 (m, 2H), 7.58 – 7.54 (m, 0.6H), 7.06 – 7.03 (m, 0.4H), 7.00 – 6.92 (m, 2H), 5.28 (s, 0.6H), 4.37 (q, *J* = 8.0 Hz, 2H), 3.37 (s, 1H), 3.35 (s, 2H), 2.99 (d, *J* = 16.0 Hz, 0.6H), 2.76 (d, *J* = 16.0 Hz, 0.4H), 2.55 (d, *J* = 16.0 Hz, 0.4H), 2.14 (d, *J* = 16.0 Hz, 0.6H), 1.38 (t, *J* = 8.0 Hz, 1.2H), 1.34 (t, *J* = 8.0 Hz, 1.8H); ¹³C NMR (101 MHz, CDCl₃): δ 182.39, 182.37, 179.76, 178.74, 178.51, 178.50, 168.10, 166.66, 155.31, 154.17, 145.19, 145.00, 135.17, 134.63, 134.58, 134.50, 133.92,


133.74, 131.43, 130.89, 130.82, 130.38, 129.79, 127.88, 126.90, 126.87, 126.68, 126.52, 124.04, 123.20, 122.23, 121.30, 120.86, 120.35, 110.29, 109.23, 96.99, 95.07, 64.20, 63.10, 46.47, 45.25, 37.26, 36.66, 27.36, 27.28, 14.14, 14.06; IR: 3423.7, 2926.4, 1750.8, 1720.8, 1656.3, 1620.8, 1607.3, 1333.3, 1302.7, 1161.4, 977.8, 717.9, 688.9, 590.1, 481.4 cm^{-1} ; HRMS-ESI: calcd. for $\text{C}_{24}\text{H}_{19}\text{ClNO}_7$ [M+H]⁺ 468.0845, found: 468.0844.

Ethyl-6'-bromo-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6m



foamy solid, 28.2 mg, 55% yield; 97% ee, > 20/1 dr, $[\alpha]_D^{26} = -4.69$ ($c = 0.91$, CH_2Cl_2); [Daicel Chiraldak IA, hexane/*i*-PrOH (70:30), flow rate: 1.0 $\text{mL}\cdot\text{min}^{-1}$, $\lambda = 254$ nm, t (major) = 14.557, t (minor) = 13.511]; ¹H (400 Hz, CDCl_3): δ 8.92 (s, 0.4H), 8.13 – 8.07 (m, 1H), 7.88 – 7.81 (m, 1H), 7.71 – 7.63 (m, 2H), 7.52 – 7.50 (m, 0.6H), 7.22 – 7.08 (m, 2H), 6.94 – 6.92 (m, 0.4H), 5.21 (s, 0.6H), 4.37 (q, $J = 8.0$ Hz, 2H), 3.37 (s, 1.3H), 3.35 (s, 1.7H), 3.00 (d, $J = 16.0$ Hz, 0.6H), 2.76 (d, $J = 16.0$ Hz, 0.4H), 2.55 (d, $J = 16.0$ Hz, 0.4H), 2.14 (d, $J = 16.0$ Hz, 0.6H), 1.39 (t, $J = 8.0$ Hz, 1.35H), 1.35 (t, $J = 8.0$ Hz, 1.65H); ¹³C NMR (101 MHz, CDCl_3): δ 182.40, 182.38, 179.65, 178.73, 178.50, 178.39, 168.11, 166.65, 155.34, 154.20, 145.32, 145.12, 134.59, 134.52, 133.94, 133.76, 131.44, 130.99, 130.91, 130.85, 130.34, 128.23, 127.02, 126.92, 126.71, 126.70, 126.54, 125.21, 123.55, 122.89, 122.55, 122.29, 121.25, 120.29, 113.05, 112.03, 96.99, 95.03, 64.26, 63.12, 46.54, 45.30, 37.21, 36.58, 27.37, 27.29, 14.16, 14.08; IR: 3427.4, 2926.5, 1750.7, 1717.0, 1655.8, 1603.2, 1466.5, 1432.5, 1302.1, 1272.6, 1126.7, 1101.6, 1066.6, 976.1, 953.2, 905.4, 791.9, 744.4, 674.2, 586.9, 509.3 cm^{-1} ; HRMS-ESI: calcd. for $\text{C}_{24}\text{H}_{19}\text{BrNO}_7$ [M+H]⁺ 512.0339, found: 512.0347.


Ethyl-2-hydroxy-6'-methoxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6n



foamy solid, 29.2 mg, 63% yield; 97% ee, > 20/1 dr, $[\alpha]_D^{26} = -86.40$ ($c = 1.01$, CH_2Cl_2); [Daicel Chiraldak OD-H, hexane/*i*-PrOH (70:30), flow rate: 1.0 $\text{mL}\cdot\text{min}^{-1}$

¹, $\lambda = 254$ nm, t (major) = 12.908, t (minor)= 11.065]; ¹H (400 Hz, CDCl₃): δ 9.11 (s, 0.4H), 8.13 – 8.07 (m, 1H), 7.88 – 7.82 (m, 1H), 7.68 – 7.63 (m, 2H), 7.54 – 7.51 (m, 0.4H), 6.95 – 6.93 (m, 0.6H), 6.58 – 6.45 (m, 2H), 5.15 (s, 0.4H), 4.37 (q, $J = 8.0$ Hz, 2H), 3.82 (s, 1.70H), 3.81 (s, 1.3H), 3.36 (s, 1.7H), 3.35 (s, 1.3H), 3.00 (d, $J = 16.0$ Hz, 0.4H), 2.77 (d, $J = 16.0$ Hz, 0.6H), 2.53 (d, $J = 16.0$ Hz, 0.6H), 2.13 (d, $J = 16.0$ Hz, 0.4H), 1.38 (t, $J = 8.0$ Hz, 1.7H), 1.35 (t, $J = 8.0$ Hz, 1.3H); ¹³C NMR (101 MHz, CDCl₃): δ 182.48, 182.47, 180.33, 179.08, 178.73, 168.34, 166.87, 161.01, 160.59, 155.10, 153.98, 145.28, 145.08, 134.45, 134.39, 133.75, 133.60, 131.60, 131.58, 130.94, 130.88, 127.56, 126.80, 126.71, 126.61, 126.52, 123.62, 123.52, 122.93, 121.93, 121.06, 107.81, 106.07, 100.11, 97.65, 97.15, 96.46, 95.17, 64.15, 62.99, 55.72, 55.57, 46.35, 45.11, 37.66, 36.93, 27.25, 27.19, 14.17, 14.08.; IR: 3431.8, 2926.2, 1749.7, 1714.8, 1682.2, 1656.0, 1619.9, 1332.0, 1269.1, 1221.4, 1201.7, 980.4, 832.2, 796.7, 721.2, 687.2, 424.1 cm⁻¹; HRMS-ESI: calcd. for C₂₅H₂₂NO₈ [M+H]⁺ 464.1340, found: 464.1344.


Ethyl-7'-fluoro-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6o



foamy solid, 27.5 mg, 61% yield; 93% ee, > 20/1 dr, $[\alpha]_D^{26}$ = - 23.30 (c = 0.78, CH₂Cl₂); [Daicel Chiraldak IA, hexane/i-PrOH (70:30), flow rate: 1.0 mL·min⁻¹, $\lambda = 254$ nm, t (major) = 13.161, t (minor)= 15.137]; ¹H (400 Hz, CDCl₃): δ 9.00 (s, 0.55H), 8.14 – 8.08 (m, 1H), 7.89 – 7.83 (m, 1H), 7.70 – 7.65 (m, 2H), 7.45 – 7.43 (m, 0.4H), 7.11 – 7.05 (m, 0.6H), 7.03 – 6.98 (m, 1H), 6.91 – 6.83 (m, 1H), 5.15 (s, 0.45H), 4.38 (q, $J = 8.0$ Hz, 2H), 3.59 – 3.58 (m, 3H), 3.02 (d, $J = 16.0$ Hz, 0.4H), 2.76 (d, $J = 16.0$ Hz, 0.6H), 2.58 (d, $J = 16.0$ Hz, 0.6H), 2.18 (d, $J = 16.0$ Hz, 0.4H), 1.39 (t, $J = 8.0$ Hz, 1.7H), 1.35 (t, $J = 8.0$ Hz, 1.3H); ¹³C NMR (101 MHz, CDCl₃): 182.39, 182.36, 179.42, 178.79, 178.56, 178.34, 178.22, 168.18, 166.68, 155.21, 154.11, 148.11 ($J = 244$ Hz), 145.57 ($J = 248$ Hz), 144.31, 134.55 ($J = 7$ Hz), 133.92, 133.75, 131.49, 131.47, 130.91 ($J = 6$ Hz), 126.92, 126.72, 126.55, 124.91, 124.89, 124.84, 122.73, 122.70, 122.67, 121.43, 120.53, 118.13, 118.10, 117.61, 117.33 ($J = 19$ Hz), 116.79 ($J = 19$ Hz), 97.07, 95.02,


64.29, 63.10, 47.04, 47.02, 37.48, 36.80, 29.90, 29.85, 14.17, 14.09; IR: 3419.4, 2984.2, 1751.4, 1720.0, 1683.7, 1656.0, 1621.7, 1594.4, 1270.8, 1203.1, 1160.4, 1059.4, 1017.6, 924.4, 790.3, 735.4, 723.6, 565.2, 456.3 cm⁻¹; HRMS-ESI: calcd. for C₂₄H₁₉FNO₇ [M+H]⁺ 452.1140, found: 452.1119.

Ethyl-2-hydroxy-1',7'-dimethyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6p



foamy solid, 35.8 mg, 70% yield; 98% *ee*, > 20/1 *dr*, $[\alpha]_D^{26} = -40.00$ (*c* = 1.33, CH₂Cl₂); [Daicel Chiraldak OD-H, hexane/*i*-PrOH (70:30), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 12.474, t (minor) = 8.329]; ¹H (400 Hz, CDCl₃): δ 9.26 (s, 0.7H), 8.13–8.07 (m, 1H), 7.88 – 7.82 (m, 1H), 7.70 – 7.62 (m, 2H), 7.08 – 7.01 (m, 1H), 6.96 – 6.82 (m, 2H), 5.15 (s, 0.3H), 4.36 (q, *J* = 8.0 Hz, 2H), 3.64 (s, 3H), 3.01 (d, *J* = 16.0 Hz, 0.2H), 2.73 (d, *J* = 16.0 Hz, 0.8H), 2.66 (s, 2.2H), 2.65 (s, 0.8H), 2.53 (d, *J* = 16.0 Hz, 0.8H), 2.14 (d, *J* = 16.0 Hz, 0.2H), 1.38 (t, *J* = 8.0 Hz, 2.2H), 1.34 (t, *J* = 8.0 Hz, 0.8H); ¹³C NMR (101 MHz, CDCl₃): δ 182.54, 182.37, 180.36, 179.38, 178.69, 168.31, 166.82, 155.12, 154.07, 141.63, 141.46, 134.43, 134.36, 133.74, 133.59, 133.12, 132.69, 132.64, 132.15, 131.55, 130.93, 130.88, 126.80, 126.67, 126.60, 126.50, 124.68, 124.06, 122.13, 121.97, 121.19, 121.07, 120.19, 119.87, 97.14, 95.15, 64.11, 62.95, 46.30, 45.08, 37.88, 37.07, 30.66, 19.46, 19.06, 14.15, 14.06; IR: 3438.6, 2925.8, 1751.4, 1709.4, 1657.6, 1618.2, 1596.4, 1458.8, 1356.1, 1333.2, 1202.7, 1171.8, 977.9, 956.9, 787.7, 747.2, 598.8, 542.5 cm⁻¹; HRMS-ESI: calcd. for C₂₅H₂₂NO₇ [M+H]⁺ 448.1391, found: 448.1402.


Ethyl-2-hydroxy-1',5',7'-trimethyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6q



foamy solid, 32.3 mg, 70% yield; 94% *ee*, > 20/1 *dr*, $[\alpha]_D^{26} = -44.40$ (*c* = 1.27, CH₂Cl₂); [Daicel Chiraldak IA, hexane/*i*-PrOH (70:30), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 11.668, t (minor) = 7.381]; ¹H (400 Hz, CDCl₃): δ 9.32 (s, 0.8H), 8.13 – 8.10 (m, 1H), 7.86 – 7.84


(m, 1H), 7.70 – 7.63 (m, 2H), 6.87 – 6.83 (m, 1H), 6.69 (s, 1H), 5.10 (s, 0.2H), 4.37 (q, J = 8.0 Hz, 2H), 3.61 (s, 3H), 2.72 (d, J = 16.0 Hz, 1H), 2.61 (s, 3H), 2.51 (d, J = 16.0 Hz, 1H), 2.20 (s, 2.4H), 2.19 (s, 0.6H), 1.38 (t, J = 8.0 Hz, 2.4H), 1.34 (t, J = 8.0 Hz, 0.6H); ^{13}C NMR (101 MHz, CDCl_3): δ 182.41, 180.24, 178.73, 166.89, 155.12, 138.98, 134.41, 133.72, 133.58, 132.77, 131.61, 130.97, 126.79, 126.56, 121.31, 120.94, 120.72, 97.18, 62.94, 46.36, 38.02, 30.61, 20.91, 18.89, 14.16; IR: 3425.9, 2923.9, 1750.3, 1709.5, 1682.6, 1658.8, 1579.1, 1477.9, 1332.4, 1203.7, 1100.9, 981.6, 956.2, 861.6, 779.1, 761.3, 647.6, 531.6 cm^{-1} ; HRMS-ESI: calcd. for $\text{C}_{26}\text{H}_{24}\text{NO}_7$ [M+H] $^+$ 462.1547, found: 462.1554.

Ethyl-5',6'-difluoro-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6r




foamy solid, 36.6 mg, 78% yield; 95% ee, > 20/1 *dr*, $[\alpha]_D^{26} = -5.97$ ($c = 1.79$, CH_2Cl_2); [Daicel Chiraldak IA, hexane/*i*-PrOH (70:30), flow rate: 1.0 $\text{mL}\cdot\text{min}^{-1}$, $\lambda = 254$ nm, t (major) = 15.728, t (minor) = 11.683]; ^1H (400 Hz, CDCl_3): δ 8.90 (s, 0.3H), 8.11 – 8.03 (m, 1H), 7.87 – 7.82 (m, 1H), 7.71 – 7.63 (m, 2H), 7.58 – 7.53 (m, 0.7H), 6.97 – 6.93 (m, 0.3H), 6.87 – 6.74 (m, 1H), 5.44 (s, 0.6H), 4.36 (q, J = 8.0 Hz, 2H), 3.35 (s, 1H), 3.31 (s, 2H), 2.98 (d, J = 16.0 Hz, 0.7H), 2.74 (d, J = 16.0 Hz, 0.3H), 2.56 (d, J = 16.0 Hz, 0.3H), 2.16 (d, J = 16.0 Hz, 0.7H), 1.38 (t, J = 8.0 Hz, 0.8H), 1.34 (t, J = 8.0 Hz, 2.2H); ^{13}C NMR (101 MHz, CDCl_3): δ 182.43, 182.40, 178.67, 178.34, 167.94, 166.59, 154.16, 134.64, 134.56, 134.00, 133.81, 131.38, 130.87, 130.79, 126.94, 126.72, 126.66, 126.53, 121.04, 117.07, 116.86, 112.45, 112.24, 98.62, 98.39, 96.95, 95.07, 64.20, 63.16, 46.70, 45.52, 37.82, 36.61, 27.49, 27.41, 14.12, 14.04; IR: 3423.6, 2928.6, 1751.5, 1722.2, 1683.8, 1594.0, 1580.1, 1470.5, 1395.8, 1333.3, 1250.5, 1095.0, 948.4, 885.3, 833.2, 780.1, 763.0, 721.2, 691.3, 618.1, 505.3 cm^{-1} ; HRMS-ESI: calcd. for $\text{C}_{24}\text{H}_{18}\text{F}_2\text{NO}_7$ [M+H] $^+$ 470.1046, found: 470.1044.

Methyl-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6s



foamy solid, 31.0 mg, 74% yield; >99% *ee*, > 20/1 *dr*, $[\alpha]_D^{26} = -40.42$ (*c* = 1.41, CH₂Cl₂); [Daicel Chiraldak IA, hexane/*i*-PrOH (70:30), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 17.990]; ¹H (400 Hz, CDCl₃): δ 9.22 (s, 0.7H), 8.13 – 8.06 (m, 1H), 7.85 – 7.80 (m, 1H), 7.70 – 7.63 (m, 2.3H), 7.38 – 7.29 (m, 1H), 7.09 – 6.94 (m, 2.7H), 5.29 (s, 0.3H), 3.92 (s, 3H), 3.39 (s, 2H), 3.37 (s, 1H), 3.02 (d, *J* = 16.0 Hz, 0.3H), 2.81 (d, *J* = 16.0 Hz, 0.7H), 2.56 (d, *J* = 16.0 Hz, 0.7H), 2.17 (d, *J* = 16.0 Hz, 0.3H); ¹³C NMR (101 MHz, CDCl₃) δ 182.33, 182.30, 179.68, 179.44, 178.67, 178.42, 168.71, 167.31, 155.12, 153.98, 134.50, 134.42, 133.79, 133.61, 131.99, 131.53, 131.48, 130.90, 130.82, 129.39, 129.34, 128.86, 126.84, 126.76, 126.70, 126.62, 126.54, 124.24, 122.37, 122.25, 122.19, 120.89, 109.44, 108.51, 97.15, 95.22, 54.37, 53.68, 46.80, 45.53, 37.45, 36.81, 27.25, 27.16; IR: 3432.1, 2926.2, 1754.3, 1712.4, 1655.6, 1579.5, 1474.4, 1437.9, 1356.2, 1333.1, 1202.1, 1096.2, 1026.8, 972.5, 796.0, 753.9, 723.4, 684.6, 543.0 cm⁻¹; HRMS-ESI: calcd. for C₂₃H₁₈NO₇ [M+H]⁺ 420.1078, found: 420.1074.

Ethyl-2-hydroxy-1',7-dimethyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6t




foamy solid, 37.9 mg, 85% yield; 93% *ee*, > 20/1 *dr*, $[\alpha]_D^{26} = -0.69$ (*c* = 1.43, CH₂Cl₂); [Daicel Chiraldak IA, hexane/*i*-PrOH (70:30), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 16.323, t (minor) = 22.584]; ¹H (400 Hz, CDCl₃): δ 9.15 (s, 0.65H), 7.91 – 7.87 (m, 1H), 7.75 – 7.69 (m, 1H), 7.65 – 7.64 (m, 0.35H), 7.44 – 7.28 (m, 2H), 7.09 – 6.99 (m, 2H), 6.97 – 6.93 (m, 0.65H), 5.20 (s, 0.35H), 4.37 (q, *J* = 8.0 Hz, 2H), 3.38 (s, 2H), 3.37 (s, 1H), 3.01 (d, *J* = 16.0 Hz, 0.35H), 2.78 (d, *J* = 16.0 Hz, 0.65H), 2.55 (d, *J* = 16.0 Hz, 0.65H), 2.45 (s, 2H), 2.44 (s, 1H), 2.16 (d, *J* = 16.0 Hz, 0.35H), 1.38 (t, *J* = 8.0 Hz, 1.90H), 1.35 (t, *J* = 8.0 Hz, 1.1H); ¹³C NMR (101 MHz, CDCl₃): δ 182.31, 179.78, 179.21, 178.97, 178.63, 168.35, 166.87, 155.09, 153.98, 144.97, 144.73, 143.94, 143.83, 135.17, 135.11, 132.20, 131.60, 130.84, 130.78, 129.32, 129.31,

128.82, 127.16, 126.97, 126.89, 126.82, 126.72, 124.20, 122.34, 122.25, 121.63, 120.72, 109.40, 108.49, 97.04, 95.10, 64.12, 63.00, 46.83, 45.59, 37.50, 36.74, 27.23, 27.17, 21.84, 21.18, 14.16, 14.08; IR: 3431.4, 2925.4, 1749.7, 1682.0, 1611.4, 1305.0, 1162.6, 1047.7, 1025.7, 754.8 cm⁻¹; HRMS-ESI: calcd. for C₂₅H₂₂NO₇ [M+H]⁺ 448.1391, found: 448.1386.

3.3 Synthesis of compound 7

In an ordinary tube equipped with a magnetic stirring bar, the solution of **4w** (45.1mg, 0.1 mmol, 1 equiv), TMSCl (75.6 μL, 0.6 mmol, 6 equiv), in CH₃CN (1.0 mL) was stirred at rt for 30 min, and then triethylamine (83.0 μL, 0.6 mmol, 6 equiv) was added. After 12h the reaction was completed, the reaction mixture was directly loaded onto a silica gel and purified by flash chromatography (eluent: petroleum ether/ ethyl acetate = 2:1) to give desired product **7**.

Ethyl-7'-methoxy-1-methyl-2,10'-dioxo-2'-(trimethylsilyloxy)-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 7




white solid, melting point: 71–73 °C, 27.3 mg, 52% yield; 97% ee, > 20/1 dr, [α]_D²⁶ = -30.59 (c = 0.68, CHCl₃); [Daicel Chiralpak AD, hexane/*i*-PrOH (70:30), flow rate: 1.0 mL·min⁻¹, λ = 254 nm, t (major) = 16.431, t (minor) = 19.872]; ¹H NMR (400 MHz, CDCl₃) δ 8.10 (d, *J* = 8.8 Hz, 1H), 7.70 (dd, *J* = 7.6, 0.8 Hz, 1H), 7.39 (td, *J* = 7.6, 1.2 Hz, 1H), 7.08 (td, *J* = 7.6, 1.2 Hz, 1H), 6.97 (d, *J* = 7.6 Hz, 1H), 6.87 (dd, *J* = 8.8, 2.4 Hz, 1H), 6.50 (d, *J* = 2.4 Hz, 1H), 4.31 (td, *J* = 7.2, 0.8 Hz, 2H), 3.78 (s, 3H), 3.33 (s, 3H), 2.97 (d, *J* = 14.0 Hz, 1H), 2.44 (d, *J* = 14.0 Hz, 1H), 1.34 (t, *J* = 7.2 Hz, 3H), 0.25 (s, 9H); ¹³C NMR (101 MHz, CDCl₃) δ 175.72, 171.07, 168.71, 164.01, 156.87, 146.96, 143.87, 136.55, 130.41, 129.43, 127.48, 127.04, 123.06, 117.68, 114.52, 108.69, 100.05, 95.35, 62.80, 55.88, 49.71, 40.95, 27.26, 14.16, 1.15; IR: 2987.8, 2943.8, 1767.6, 1725.3, 1768.7, 1600.5, 1623.4, 1430.3, 1294.9, 1276.7, 1246.7, 933.4, 904.8, 888.7, 838.8, 794.3 cm⁻¹; HRMS-ESI: calcd. for C₂₇H₃₀NO₈Si [M+H]⁺ 524.1735, found: 524.1745.

3.4 Synthesis of compound 8

In an ordinary tube equipped with a magnetic stirring bar, the solution of **6a** (64.9 mg, 0.15 mmol, 1 equiv), mesyl chloride (19.2 μ L, 0.25 mmol 1.67 equiv), in DCM (1.0 mL) was stirred at rt. for 30 min, and then triethylamine (34.6 μ L, 0.25 mmol, 1.67 equiv) was added. After 12h the reaction was finished, the reaction mixture was directly loaded onto a silica gel and purified by flash chromatography (eluent: petroleum ether/ethyl acetate = 5:1) to give desired product **8**.


Ethyl-1'-methyl-2-((methylsulfonyl)oxy)-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 8





yellow solid, melting point: 124–126 °C, 73.7 mg, 96% yield; 94% *ee*, 8/1 *dr*, $[\alpha]_D^{26} = -34.05$ ($c = 0.79$, CHCl_3); [Daicel Chiralpak IA, hexane/*i*-PrOH (70:30), flow rate: 1.0 $\text{mL}\cdot\text{min}^{-1}$, $\lambda = 254$ nm, t (major) = 42.444, t (minor) = 17.437]; ^1H (400 Hz, CDCl_3): δ 8.13 (dd, $J = 7.7, 1.2$ Hz, 1H), 7.86 (dd, $J = 7.6, 1.2$ Hz, 1H), 7.73 – 7.64 (m, 2H), 7.45 (dd, $J = 7.6, 0.8$ Hz, 1H), 7.36 (td, $J = 7.6, 1.2$ Hz, 1H), 7.03 (td, $J = 7.6, 1.2$ Hz, 1H), 6.99 (d, $J = 8.0$ Hz, 1H), 4.39 (qd, $J = 7.2, 2.8$ Hz, 2H), 3.36 (s, 3H), 3.25 (s, 3H), 2.74 (d, $J = 14.4$ Hz, 1H), 2.59 (d, $J = 14.4$ Hz, 1H), 1.36 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3): δ 182.00, 177.31, 164.76, 152.65, 144.02, 134.57, 134.06, 131.30, 130.89, 130.78, 129.39, 126.92, 126.76, 125.70, 122.79, 121.80, 109.00, 99.15, 64.10, 45.36, 41.30, 38.67, 27.25, 13.96; IR: 2987.8, 2943.8, 1767.6, 1725.3, 1768.7, 1600.5, 1623.4, 1430.3, 1294.9, 1276.7, 1246.7, 933.4, 904.8, 888.7, 838.8, 794.3 cm^{-1} ; HRMS-ESI: calcd. for $\text{C}_{25}\text{H}_{21}\text{NNaO}_7\text{S} [\text{M}+\text{Na}]^+$ 534.0829, found: 534.0827.

4. ^1H NMR and ^{13}C NMR spectra



Ethyl-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4a





**Ethyl 2'-hydroxy-1-(methoxymethyl)-2,10'-dioxo-2',3'-dihydro-10'H-spiro
[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4b**



Ethyl 1-benzyl-2'-hydroxy-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4c





Ethyl 1-allyl-2'-hydroxy-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4d




1-benzyl 2'-ethyl 2'-hydroxy-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-

3,4'-pyrano[3,2-*b*]chromene]-1,2'-dicarboxylate 4e





Ethyl 1-acetyl-2'-hydroxy-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-

3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate **4f**





Ethyl 5-fluoro-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro

[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4g




4g



4g



Ethyl 5-chloro-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro

[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4h





Ethyl 5-bromo-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro

[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4i




Ethyl 2'-hydroxy-1,5-dimethyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro

[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate **4j**







Ethyl 2'-hydroxy-5-methoxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro

[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4k





Ethyl 6-chloro-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro

[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4l




Ethyl 6-bromo-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro

[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4m







Ethyl 2'-hydroxy-6-methoxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro-

[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4n







Ethyl 7-fluoro-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro

[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4o







Ethyl 2'-hydroxy-1,7-dimethyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro

[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4p







Ethyl 2'-hydroxy-1,5,7-trimethyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro

[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4q





Ethyl 5,6-difluoro-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro

[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4r




Methyl 2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro

[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate **4s**




Ethyl 8'-fluoro-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro

[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate **4t**




Ethyl 8'-bromo-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro

[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate **4u**





Ethyl 2'-hydroxy-1,8'-dimethyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro

[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate **4v**




Ethyl 2'-hydroxy-7'-methoxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-



spiro[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4w





Ethyl-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate^{6a}





Ethyl-2-hydroxy-1'-(methoxymethyl)-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6b




Ethyl-1'-benzyl-2-hydroxy-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6c





Ethyl-1'-allyl-2-hydroxy-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6d





1'-benzyl-2-ethyl-2-hydroxy-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-1',2-dicarboxylate 6e





Ethyl-1'-acetyl-2-hydroxy-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6f





Ethyl-5'-fluoro-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6g





Ethyl-5'-chloro-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6h





Ethyl-5'-bromo-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6i





Ethyl-2-hydroxy-1',5'-dimethyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6j




Ethyl-2-hydroxy-5'-methoxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6k





Ethyl-6'-chloro-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6l




Ethyl-6'-bromo-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6m





Ethyl-2-hydroxy-6'-methoxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6n




Ethyl-7'-fluoro-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6o




Ethyl-2-hydroxy-1',7'-dimethyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6p




Ethyl-2-hydroxy-1',5',7'-trimethyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6q




Ethyl-5',6'-difluoro-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6r





Methyl-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6s




Ethyl-2-hydroxy-1',7-dimethyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6t



Ethyl-1-methyl-2,10'-dioxo-2'-(trimethylsilyl)oxy)-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 7




Ethyl-1'-methyl-2-((methylsulfonyl)oxy)-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 8




5. HPLC spectra

Ethyl 2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4a




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
----- ----- ----- ----- ----- ----- -----						
1	14.040	BB	0.7338	3217.62280	65.42322	49.3172
2	24.202	BB	0.8686	3306.72314	56.84908	50.6828
Totals :				6524.34595	122.27230	




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
----- ----- ----- ----- ----- ----- -----						
1	13.936	BB	0.7537	9152.50684	180.44893	99.1264
2	24.650	MM R	0.8756	80.65916	1.53531	0.8736
Totals :				9233.16600	181.98424	

Ethyl 2'-hydroxy-1-(methoxymethyl)-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4b




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	12.430	BB	0.5780	2102.57446	54.26806	48.8232
2	17.008	BB	0.6257	2203.93457	52.50396	51.1768
Totals :					4306.50903	106.77202



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	12.362	BB	0.5892	7103.74316	178.13443	98.7620
2	17.090	BB	0.4822	89.04506	2.30777	1.2380


Totals : 7192.78822 180.44220

Ethyl 1-benzyl-2'-hydroxy-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-b]chromene]-2'-carboxylate 4c




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	18.019	BB	0.8315	2409.38428	42.23662	49.4604
2	25.375	BB	0.8960	2461.95923	39.78049	50.5396

Totals : 4871.34351 82.01712




Totals : 3.13307e4 486.16054

Ethyl 1-allyl-2'-hydroxy-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-b]chromene]-2'-carboxylate 4d




Totals : 4605.37573 94.24804




Totals : 5152.40163 97.17303

1-benzyl 2'-ethyl-2'-hydroxy-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-b]chromene]-1,2'-dicarboxylate4e




Totals : 4126.85620 44.35450



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	28.027	BB	1.3364	6737.96045	72.09135	98.7080
2	41.336	MM R	1.6883	88.19569	8.70631e-1	1.2920


Totals : 6826.15614 72.96198

Ethyl 1-acetyl-2'-hydroxy-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyran[3,2-*b*]chromene]-2'-carboxylate4f



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	15.413	BB	1.1217	3484.34009	42.62595	48.1464
2	19.703	BB	0.7818	3752.62231	73.97834	51.8536


Totals : 7236.96240 116.60429




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	15.747	BB	0.9784	1146.07373	14.49519	97.9738
2	20.035	MM R	0.6677	23.70196	5.91638e-1	2.0262

Totals : 1169.77569 15.08683


Ethyl 5-fluoro-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro [indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4g




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
----- ----- ----- ----- ----- ----- -----						
1	30.533	BB	1.0605	1111.14148	12.45931	49.0738
2	33.716	BB	1.0111	1153.08521	13.85361	50.9262
Totals :						
				2264.22668	26.31292	



Ethyl 5-chloro-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro [indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4h





Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	27.251	BB	1.2416	4336.33936	49.52062	50.3223
2	30.680	BB	1.4080	4280.78809	44.27415	49.6777
Totals :					8617.12744	93.79477



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	28.046	MM R	0.7436	138.00710	2.20083	3.0503
2	30.714	BB	1.3623	4386.33057	47.02105	96.9497
Totals :					4524.33766	49.22188


Ethyl 5-bromo-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro [indoline-3,4'-pyrano[3,2-b]chromene]-2'-carboxylate 4i






Totals : 1.03575e4 154.31380

Ethyl 2'-hydroxy-1,5-dimethyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-b]chromene]-2'-carboxylate 4j




Totals : 9594.73535 155.71078




Totals : 4648.75871 69.06931

Ethyl 2'-hydroxy-5-methoxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro [indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4k




Totals : 7748.00269 84.49311



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	22.303	BB	1.3751	1.60207e4	167.60925	99.0847
2	27.639	MM R	1.0050	147.99214	2.45422	0.9153
Totals :						1.61687e4 170.06347


Ethyl 6-chloro-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyran]-2'-carboxylate 4l

DAD1 A, Sig=254.4 Ref=360,100 (E:\WXW\DATA\YSJ\20151020\YSJ000052.D)



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	22.967	BB	0.9890	1571.45581	22.43939	49.0396
2	30.324	BB	1.1269	1633.00806	20.64290	50.9604
Totals :						3204.46387 43.08228


DAD1 A, Sig=254.4 Ref=360,100 (E:\WXW\DATA\YSJ\20151020\YSJ000053.D)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	22.883	BB	1.0257	1828.51318	26.02448	98.2637
2	30.794	MM R	1.1908	32.30936	4.52210e-1	1.7363
Totals :						1860.82255 26.47669

Ethyl 6-bromo-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-b]chromene]-2'-carboxylate 4m

DAD1 A, Sig=254.4 Ref=360,100 (E:\WXW\DATA\YSJ\20151020\YSJ000171.D)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	22.966	BB	0.9657	1494.78760	21.53656	49.2990
2	30.766	BB	1.1229	1537.30017	18.54871	50.7010
Totals :				3032.08777	40.08527	





Ethyl 2'-hydroxy-6-methoxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro [indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4n

DAD1 A, Sig=254,4 Ref=360,100 (E:\WXW\DATA\YSJ\20151020\YSJ000173.D)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	25.994	MM R	1.7062	1034.94873	10.10994	50.1373
2	36.138	MM R	1.8427	1029.28235	9.30976	49.8627
Totals :				2064.23108	19.41970	

DAD1 A, Sig=254,4 Ref=360,100 (E:\WXW\DATA\YSJ\20151020\YSJ000174.D)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	26.010	BB	1.1677	1338.87024	13.58643	100.0000
Totals :				1338.87024	13.58643	

Ethyl 7-fluoro-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro [indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate **4o**





Peak RetTime Type		Width	Area	Height	Area
#	[min]	[min]	[mAU*s]	[mAU]	%
<hr/>					
1	19.695	MM R	1.3759	2670.78442	32.35140
2	38.992	MM R	1.6375	2650.27881	26.97417
Totals :			5321.06323	59.32557	




Totals : 6929.33700 76.72041

Ethyl 2'-hydroxy-1,7-dimethyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4p




Ethyl 2'-hydroxy-1,5,7-trimethyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4q



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	18.322	BV	1.1735	4480.33936	52.29545	49.6593
2	21.432	VB	1.5225	4541.81445	39.58774	50.3407
Totals :						9022.15381 91.88319


DAD1 A, Sig=254.4 Ref=360,100 (E:\WXW\DATA\YSJ\20151020\YSJ000008.D)



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	19.769	MM R	0.6400	64.79082	1.22321	1.2766
2	21.379	BB	1.5345	5010.36963	45.08607	98.7234
Totals :						5075.16045 46.30928


Ethyl 5,6-difluoro-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro [indoline-3,4'-pyranos[3,2-b]chromene]-2'-carboxylate 4r

DAD1 A, Sig=254.4 Ref=360,100 (E:\WXW\DATA\YSJ\20151020\YSJ000054.D)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	22.262	BB	0.8865	6490.21143	109.97916	50.0013
2	26.375	BB	1.1830	6489.86816	82.92921	49.9987
Totals :						1.29801e4 192.90836

DAD1 A, Sig=254.4 Ref=360,100 (E:\WXW\DATA\YSJ\20151020\YSJ000055.D)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	22.295	BB	0.9528	1.61579e4	256.55420	96.3889
2	27.049	BB	0.8077	605.34357	9.42067	3.6111
Totals :					1.67632e4	265.97487

Methyl-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyranoo[3,2-*b*]chromene]-2'-carboxylate 4s




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	20.504	MM R	1.4593	1260.40442	14.39524	49.9723
2	31.655	MM R	1.6140	1261.79944	13.02959	50.0277
Totals :					2522.20386	27.42484




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	20.279	BB	1.1899	8348.59961	101.04670	98.9346
2	32.183	MM R	1.5266	89.90571	9.81533e-1	1.0654
Totals :					8438.50532	102.02823

Ethyl 8'-fluoro-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro [indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4t

DAD1 A, Sig=254,4 Ref=360,100 (E:\WXW\DATA\YSJ\20151020\YSJ000110.D)




DAD1 A, Sig=254,4 Ref=360,100 (E:\WXW\DATA\YSJ\20151020\YSJ000111.D)



Totals : 4372.64951 83.62153

Ethyl 8'-bromo-2'-hydroxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro [indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate 4u


DAD1 A, Sig=254,4 Ref=360,100 (E:\WXW\DATA\YSJ\20151020\YSJ000112.D)



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	15.500	BB	0.9360	4312.88428	68.74043	49.8998
2	31.134	BB	1.0639	4330.20850	60.58333	50.1002

Totals : 8643.09277 129.32376

DAD1 A, Sig=254.4 Ref=360,100 (E:\WXW\DATA\YSJ\20151020\YSJ000113.D)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	15.695	BB	1.0187	9002.20996	133.16742	95.9956
2	31.396	BB	0.8082	375.52078	5.47481	4.0044

Totals : 9377.73074 138.64223


Ethyl 2'-hydroxy-1,8'-dimethyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-b]chromene]-2'-carboxylate 4v

DAD1 A, Sig=254.4 Ref=360,100 (E:\WXW\DATA\YSJ\20151020\YSJ000114.D)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	19.776	MM R	1.2252	2524.61938	34.34168	50.0575
2	40.438	BB	1.3200	2518.82397	26.95934	49.9425

Totals : 5043.44336 61.30102




Totals : 7867.87157 96.14715



Ethyl 2'-hydroxy-7'-methoxy-1-methyl-2,10'-dioxo-2',3'-dihydro-10'H-spiro [indoline-3,4'-pyrano[3,2-*b*]chromene]-2'-carboxylate **4w**



Totals : 9249.77393 126.74802




Ethyl-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6a



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	17.981	BB	0.6157	2696.38379	66.69093	99.1704
2	22.054	MM	0.3451	22.55664	8.12515e-1	0.8296
Totals :					2718.94043	67.50345



Ethyl-2-hydroxy-1'-(methoxymethyl)-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6b




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.124	MM R	0.5240	47.47104	1.50998	1.4911
2	16.117	BB	1.1544	3136.22583	40.63460	98.5089

Totals : 3183.69687 42.14458

Ethyl-1'-benzyl-2-hydroxy-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6c




Ethyl-1'-allyl-2-hydroxy-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6d



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	14.786	BV	0.5107	7334.21973	217.90457	49.1801
2	16.247	VB	0.6968	7578.76611	157.10030	50.8199

Totals : 1.49130e4 375.00487

DAD1 A, Sig=254.4 Ref=360,100 (E:\WXW\DATA\ZSY\20141114\CX00032.D)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	14.892	BB	0.4700	107.36703	3.40346	1.8652
2	16.315	BB	0.6798	5648.83252	120.75301	98.1348

Totals : 5756.19955 124.15646


1'-benzyl-2-ethyl-2-hydroxy-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-1',2-dicarboxylate 6e

DAD1 A, Sig=254.4 Ref=360,100 (E:\WXW\DATA\ZSY\SNAPSHOT.D)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	24.332	BB	0.8458	3473.16821	62.16756	51.6697
2	27.392	BB	1.0721	3248.69531	44.48141	48.3303

Totals : 6721.86353 106.64897




Totals : 9258.46301 122.05457

Ethyl-1'-acetyl-2-hydroxy-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6f




Totals : 1076.53864 29.67199



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	12.719	BB	0.5367	169.73434	4.64057	1.6889
2	14.311	BB	0.5813	9880.06836	253.14079	98.3111
Totals :					1.00498e4	257.78137

Ethyl-5'-fluoro-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6g




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.603	BB	0.3962	5012.96289	187.33189	50.2219
2	13.997	BB	0.5097	4968.66504	146.50003	49.7781
Totals :					9981.62793	333.83192




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.650	BB	0.3819	93.46729	3.56514	1.5989
2	13.975	BB	0.5070	5752.07910	170.75229	98.4011
Totals :					5845.54639	174.31743

Ethyl-5'-chloro-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6h



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.921	BB	0.3486	1.06937e4	450.99490	50.2570
2	14.688	BB	0.5250	1.05844e4	301.91107	49.7430


Totals : 2.12781e4 752.90598




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.947	BB	0.3389	222.97485	9.81894	1.2845
2	14.660	BB	0.5122	1.71357e4	502.06799	98.7155

Totals : 1.73587e4 511.88693

Ethyl-5'-bromo-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6i




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.982	VB	0.3620	1.10359e4	450.25565	50.3668
2	15.071	BB	0.5459	1.08751e4	299.31036	49.6332
Totals :					2.19110e4	749.56601




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.027	BB	0.3549	81.02819	3.43909	1.2582
2	15.113	BB	0.5333	6359.01563	179.48303	98.7418
Totals :					6440.04382	182.92212

Ethyl-2-hydroxy-1',5'-dimethyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6j





Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.392	VB	0.2611	1228.95825	70.58884	50.3530
2	11.228	BB	0.3719	1211.72485	49.44472	49.6470
Totals :					2440.68311	120.03355




Totals : 9323.06390 361.47870

Ethyl-2-hydroxy-5'-methoxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6k




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.840	BB	0.4464	264.84549	8.91912	1.5432
2	13.584	BB	0.5146	1.68968e4	487.22214	98.4568
Totals :					1.71617e4	496.14126

Ethyl-6'-chloro-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6l




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	31.990	BB	1.1777	3894.71045	47.84369	50.6530
2	35.236	BB	1.2792	3794.28589	40.64005	49.3470
Totals :					7688.99634	88.48373




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	32.136	BV	0.7702	253.28360	3.87711	1.3232
2	34.813	VB	1.3462	1.88884e4	202.87770	98.6768
Totals :					1.91417e4	206.75481

Ethyl-6'-bromo-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6m

DAD1 A, Sig=254.4 Ref=360,100 (E:\WXW\DATA\ZSY\SNAPSHOT.D)



DAD1 A, Sig=254.4 Ref=360,100 (E:\WXW\DATA\ZSY\SNAPSHOT.D)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	13.511	BV	0.4278	142.38757	5.16267	1.6358
2	14.557	VB	0.5513	8562.33496	232.69293	98.3642

Totals : 8704.72253 237.85561


Ethyl-2-hydroxy-6'-methoxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6n

DAD1 A, Sig=254.4 Ref=360,100 (E:\WXW\DATA\ZSY\SNAPSHOT.D)



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.751	BV	0.9416	1595.52100	25.58156	48.9236
2	12.674	VB	1.2125	1665.72729	19.50119	51.0764
Totals :					3261.24829	45.08275

DAD1 A, Sig=254.4 Ref=360,100 (E:\WXW\DATA\ZSY\SNAPSHOT.D)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.065	MM	0.6468	80.36452	1.50776	1.5007
2	12.908	BB	1.3614	5274.90186	57.54477	98.4993

Totals : 5355.26637 59.05252


Ethyl-7'-fluoro-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate **6o**

DAD1 A, Sig=254.4 Ref=360,100 (E:\WXW\DATA\ZSY\SNAPSHOT.D)





Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	13.220	BV	0.5366	4698.39893	130.33797	49.2694
2	15.096	VB	0.5351	4837.74072	136.62614	50.7306

Totals : 9536.13965 266.96411




Ethyl-2-hydroxy-1',7'-dimethyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6p




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.329	MM	0.4899	41.33153	1.40609	1.0764
2	12.474	BB	1.0530	3798.54053	54.24078	98.9236
Totals :					3839.87206	55.64687

Ethyl-2-hydroxy-1',5',7'-trimethyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6q




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.333	BV	0.2993	8018.89600	397.64301	49.2899
2	11.667	BB	0.4415	8249.94434	280.24136	50.7101
Totals :					1.62688e4	677.88437




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.381	BB	0.3033	231.95744	11.40619	3.2345
2	11.668	BB	0.4358	6939.35742	238.27428	96.7655
Totals :					7171.31487	249.68047

Ethyl-5',6'-difluoro-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6r




Peak RetTime		Type	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	11.616	BB	0.4090	3706.02222	135.51880	50.0802
2	15.745	BB	0.5478	3694.14624	102.66139	49.9198

Totals : 7400.16846 238.18019




Totals : 4009.71298 111.29751

Methyl-2-hydroxy-1'-methyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6s




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	14.218	BB	0.5257	178.67189	5.16410	1.4451
2	16.894	BV	0.5209	151.20691	4.53598	1.2230
3	18.243	VV	0.7458	5228.24170	106.67732	42.2871
4	19.656	VB	0.7871	6805.55029	126.60309	55.0447

Totals : 1.23637e4 242.98049




Totals : 1.73121e4 308.52352

Ethyl-2-hydroxy-1',7-dimethyl-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 6t




Totals : 5183.30103 114.59322




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	16.323	BB	0.6164	1.20090e4	289.21008	96.2763
2	22.584	BB	0.7949	464.47089	8.58945	3.7237
Totals :					1.24734e4	297.79954

Ethyl-7'-methoxy-1-methyl-2,10'-dioxo-2'-(trimethylsilyl)oxy-2',3'-dihydro-10'H-spiro[indoline-3,4'-pyrano[3,2-b]chromene]-2'-carboxylate 7



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	16.217	BB	0.5539	4451.29248	123.10169	46.5760
2	18.964	BB	1.1594	5105.75879	61.44842	53.4240


Totals : 9557.05127 184.55011



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	16.431	BB	0.5693	4237.82959	114.11116	98.2993
2	19.872	MM R	0.9135	73.32010	1.33773	1.7007
Totals :					4311.14969	115.44889

Ethyl 1'-methyl-2-((methylthio)trioxidanyl)-2',5,10-trioxo-2,3,5,10-tetrahydrospiro[benzo[g]chromene-4,3'-indoline]-2-carboxylate 8


DAD1 A, Sig=254.4 Ref=360,100 (E:\WXW\DATA\YSJ\20160326\YSJ000013.D)



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.660	BB	0.2940	75.03631	3.87430	6.4299
2	17.428	BB	0.5564	506.91077	13.74205	43.4377
3	22.986	MM	0.7184	84.02094	1.94938	7.1998
4	42.546	MM	1.3177	501.01611	6.33699	42.9326


Totals : 1166.98413 25.90272

DAD1 A, Sig=254.4 Ref=360,100 (E:\WXW\DATA\YSJ\20160326\YSJ000014.D)



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.652	BB	0.2911	226.63710	11.74415	10.9727
2	17.437	MM	0.5693	54.58736	1.59797	2.6429
3	42.444	BB	1.1079	1784.23010	22.92797	86.3844
Totals :				2065.45457	36.27010	

6. Single-Crystal X-ray Crystallography of rac-4u



Identification code	g160108a
Empirical formula	C ₄₉ H ₃₆ Br ₂ N ₂ O ₁₄
Formula weight	1036.62
Temperature/K	293(2)
Crystal system	monoclinic
Space group	P2 ₁ /c
a/Å	12.7894(8)
b/Å	17.4413(12)
c/Å	10.9644(7)
α/°	90.00
β/°	96.421(6)
γ/°	90.00
Volume/Å ³	2430.4(3)
Z	2
ρ _{calc} g/cm ³	1.417
μ/mm ⁻¹	2.685
F(000)	1052.0
Crystal size/mm ³	0.3 × 0.15 × 0.1

Radiation CuK α ($\lambda = 1.54184$)
 2 Θ range for data collection/° 8.6 to 146.74
 Index ranges -15 \leq h \leq 15, -17 \leq k \leq 21, -13 \leq l \leq 11
 Reflections collected 9219
 Independent reflections 4746 [$R_{\text{int}} = 0.0478$, $R_{\text{sigma}} = 0.0698$]
 Data/restraints/parameters 4746/17/319
 Goodness-of-fit on F^2 1.083
 Final R indexes [$I \geq 2\sigma(I)$] $R_1 = 0.0653$, $wR_2 = 0.1966$
 Final R indexes [all data] $R_1 = 0.0942$, $wR_2 = 0.2246$
 Largest diff. peak/hole / e Å⁻³ 0.88/-0.40

The crystal was prepared from the solution of **4u** in ethyl acetate and n-hexane. CCDC 1446846 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.